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Australian Centre for International Agricultural Research Foreword 
Bioteclmology  comprises  a  powerful  set of modem biological  tools  and  teclmiques  with  the potential  to 
contribute to global food security. The effective application of biotechnology by ACIAR to achieve program 
objectives raises issues which need examination and discussion. 
Fortuitously, Dr Vimala Sarma, a participant of the Executive Development Scheme of the Public Service 
Commission. and previously Secretary of  the Genetic Manipulation Advisory Committee, joined ACIAR in 1994 
for  her third placement under the Scheme.  As  part of her activities  in AClAR, she was given the task of 
examining current developments in bioteclmology and their relevance to ACIAR's activities, discussing  issues 
arising from  them,  and formulating recommendations. This report represents her informed assessment of the 
issues, their significance for ACIAR, and possible mechanisms to address them. 
The  options and recommendations contained in this  report are an important contribution, and I hope will 
stimulate further debate on bioteclmology issues within ACIAR, with our partners, and perhaps more widely in 
the international agricultural development scene. 
ACIAR's country partners are developing their positions with respect to a number of important aspects of 
bioteclmology  including  intellectual  property  rights  and  biosafety.  and  ACIAR  needs  to  be responsive  to 
evolving  policy  on  these  issues,  not  the  least  being  partner  country  responses  to  obligations  under  the 
Biodiversity Convention. The significance of the links between the Biodiversity Convention and bioteclmology 
issues  are increasingly recognised in the international arena.  For example, developing countries may support 
international protocols  which may result in  conditions being attached  to  endemic germplasm prospecting by 
developed countries, aimed at germplasm enhancement through bioteclmology. 
ACIAR also needs to consider its own responses to the issues raised in this report, particularly in the light of 
the developing Australian position on bioteclmology issues. Some of these issues have wider implications which 
may need to be considered as  ACIAR develops its own policy position. ACIAR's policy response to biotech-
nology developments needs to be dynamic, in the light of rapidly changing teclmological, social and economic 
circumstances. Thus  ACIAR will be better equipped to  make the most effective use of biotechnology,  as  its 
multi-faceted dimensions unfold in the global arena, as well as domestically. 
ACIAR  is  grateful to  Dr Sarma for  this  useful  and timely contribution to  the development of ACIAR's 
thinking on the role of biotechnology in our programs. ACIAR would also like to acknowledge the favourable and 
helpful comments of Professor Bruce Holloway of Monash University, and Dr Elizabeth Heij of the Division of 




iii Terms of  Reference 
1. Taking into accOlmt ACIAR's statutory functions, mode of operation and its expanded mandate post its  1992 
'sunset review', identify the main issues relating to the use biotechnology in agricultural research funded through 
ACIAR's bilateral and multi-lateral programs. In particular, identify: 
applications in biotechnology relevant to ACIAR's research program disciplines; 
constraints  (including  institutional  and policy constraints) and opportunities for collaboration in biotech-
nology between Australia and its mandate countries; 
the strengths and weaknesses of Australia and its partner countries in the application of biotechnology, noting 
national priorities, programs and capabilities; 
policy issues, including intellectual property rights, biosafety, biodiversity,  and policy on funding biotech-
nology projects undertaken by the International Agricultural Research Centres; and 
training and research capacity building opportunities in bioteclmology, taking into account the role of other 
agencies and donors. 
2. Consider AClAR's options for appropriate policy and procedural responses to the issues identified, including 
training for ACIAR staff. 
3.  Formulate recommendations arising from  the options  to  enable ACIAR to  address institutional and policy 
constraints, and to maximise opportunities for successful bilateral and multi-lateral collaboration in agricultural 
research applying bioteclmology. 
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1. Executive Summary and 
Recommendations 
BIOTECHNOLOGY is a set of modem biological research 
tools and teclmologies which have been widely adop-
ted in research institutions in all  developed countries 
including Australia. These bioteclmologies can achieve 
objectives in agricultural research, as in all other areas 
of biological research. Bioteclmology can thus play an 
important role in development objectives for agencies 
involved in international agricultural research. 
This paper reviews the current status of biotech-
nology in agricultural research from the viewpoint of 
an  Australian Government  agency  namely  the  Aus-
tralian Centre for International Agricultural Research 
(ACIAR)  which  funds  collaborative  agricultural 
research in countries within its geographic mandate. It 
discusses  existing  issues  accentuated  by  the  use  of 
bioteclmology,  and  the  policy  implications  arising 
from these issues. It  focuses on the mode of operation, 
internal processes and procedures of ACIAR, in order 
to  identify  policies  and  procedures  to  address  the 
issues. 
Significance of Biotechnology for ACIAR 
Bioteclmology has  the  potential  to contribute  to  the 
objectives of all ACIAR's bilateral programs. In order 
to make the best choice of methods that will achieve 
these objectives, ACIAR needs to  gain an  increased 
appreciation of the scope, capabilities and limitations 
of current developments in bioteclmology. 
Recommendation 1 
That AClAR invite working scientists from 
different disciplines to explain new developments 
in biotechnology in a series of  in-house technical 
seminars. 
Recommendation 2 
As biotechnology provides a set of tools to achieve 
research objectives, it has the capacity to 
contribute to all program areas, and could be 
integrated into projects where its use is the best 
way to achieve the objectives of  the project. It can 
complement traditional research methods, and is 
most successful when augmenting pre-existing 
research strengths in the partner country. 
Recommendation 3 
That AClAR consider acquiring, developing, or 
contracting sufficient expertise to assess the feasi-
bility-of-concept in biotechnology projects, and to 
advise on issues such as biosafety and the relative 
capabilities of  particular institutes to carry out 
biotechnology projects at the m-house review 
process. 
Policy Issues Associated with Biotechnology 
The most important policy implications arising from 
bioteclmology  for  ACIAR's  bilateral programs  arise 
from  issues  surrounding  the  equitable  allocation  of 
intellectual  property  rights  (IPR)  and  biosafety. 
Proposed projects  in ACIAR  go  through a  thorough 
development  stage  (Phases  1-4) where  such  issues 
could be taken into account. A number of steps could 
be taken to ensure that the research arising from the 
use of biotechnology, if commercialised, is accessible 
to  ACIAR's  partner  countries  involved  in  the  re-
search,  and· that  IPR  is  equitably  distributed  and 
managed. 
Recommendation 4 
If  there is potential for a marketable product to be 
developed from the research,  where feasible,  an 
Australian  company  capable  of marketing  the 
product  overseas  might  be  associated  with  the 
project from its inception, and efforts be made, to 
secure  appropriate  proportional  (or  matching) 
funding from the company. 
Recommendation 5 
That AClAR's policy o/the equitable allocation of 
intellectual property  rights (!PR)  is  appropriate for biotechrwlogy, and that the Phase 2 proforma 
be amended to seek a statemenl on the allocation 
of  [PR from the commissioned organisation at lJutf 
stage  of project  developmenl.  ACIAR  could 
examine the  mechanism of compulsory  licensing 
arrangemenls for spillover benefits to other devel-
oping  COUnlries  which  might  otherwise  find  it 
difficult to access the product. 
The biosafety of research arising from genetic manipu-
lation research is  also  an  important consideration at 
the  project  development stage.  Genetically  manipu-
lated constructs arising from the research need to  be 
assessed and field-tested so that any potential hazard is 
identified  and  the  trial monitored. There are ethical 
concerns with animal experimentation, and consumer 
acceptance and regulation of genetically manipulated 
foods,  which  raises  issues  that  require  appropriate 
criteria to be met at the project design stage. It is not 
ACIAR's role to  conduct such assessments but there 
might be awareness of the criteria to be met, and the 
responsibility  for  undertaking  clearances  should  be 
identified and clarified in the project documentation. 
Recommendation 6 
Ac/AR's Research Program Coordinators should 
be aware of the criteria for  biosafety  and food 
safety  assessmenl at the stage when the genetic 
construct is planned, if  a genetically manipulated 
organism is COnlemplated in the proposal. 
Recommendation 7 
The  project pro-forma  at  the  Phase  2  stage of 
project deveiopmenl should require explicitly, tJutt 
the  Australian project  leader  take  responsibility 
for obtaining any  necessary approvals,  including 
ethical approval for animal experimentation,from 
institutional  ethics  committees  within  the  Aust· 
ralian  commissioned  organisation,  and for  any 
clearances for genetic manipulation work falling 
under the guidelines of  the Genetic ManipUlation 
Advisory Committee (GMAC). 
As the regulatory systems in ACIAR's partner coun-
tries  for  biosafety  assessment  are  variable,  ACIAR 
would need to formally notify its parlners of any pro-
posed release  of genetically  manipulated organisms 
associated  with  a  project,  and  where  there  are  no 
national assessment procedures, further measures m:.y 
be necessary to safeguard ACIAR's position. 
Recommendation 8 
If the field trialing of a geneticaIIy manipulated 
organism (GMO) in a partner country is proposed 
in a  project, Ac/AR should formally  advise  the 
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relevanl Ministry in the partner country of  the fact 
prior  to  the  release  of the  GMO  so  that  any 
necessary clearances can be obtained. This notifi-
cation  can  be  undertaken  with  the  contractual 
documentation for the project, or subsequenlly, if 
the release was not  foreseen at the inception of  the 
project.  Where  feasible,  GMAC  advice  on  the 
monitoring  requirements  of the  trial  should  be 
senl to the Project Leader in the partner COUnlry. 
Recommendation 9 
Where it is clear that the partner counlry has no 
regulatory or advisory system for the assessment 
of  the environmental release of genetically manip-
ulated organisms, the advice of  the in-house bio-
safety  committee  of the  relevanl  inlernational 
agricultural research  centre  could be sought,  if 
such a centre exists in that country. If  not, ACIAR 
may need to assume the responsibility for commis-
sioning such assessment in the partner country. 
Multilateral Issues 
Australia  has  signed  and  ratified  the  Biodiversity 
Convention  and  currently  domestic  discussions  are 
underway on access to  Australia's germplasm, and on 
Australia's position on the need for  a biosafety proto-
col. Any decision on the need for a protocol under the 
Convention will have  an impact on ACIAR's activ-
ities. Multilateral issues arise from the use of biotech-
nology but these issues are not confined to biotech-
nology only. These issues relate to collection, and safe 
transfer and exchange of germplasm, including germ-
plasm  improved  by  the  use  of biotechnologies.  In 
order to  implement and take into account Australia's 
obligations under the Convention, these measures are 
recommended: 
Recommendation 10 
Where  it  is  envisaged  that  germplasm  is  to  be 
collected in a project, the Memorandum of  Under-
standing  (MOU)  for  the  project  should  fore-
shadow this, and seek approval from the national 
government of  the partner country under mutually 
acceptable terms. 
Recommendation 11 
That liaison with the Commonwealth Department 
of Foreign Affairs and Trade  be strengthened so 
that ACIAR is represented on relevanl Australian 
Governmenl inter-departmenlal committees set up 
to consider Australia's obligations under the Bio-
diversity  Convention,  a.nd  on  any  international 
expert meetings related to the Convention. ACIAR's Act was reviewed after 10 years of opera-
tion in 1992. As a result of  the 'sunset' review, AClAR 
was given the responsibility for Australia's allocation 
to the network of International Agricultural Research 
Centres (lARCs). IARCs serve as important reposi-
tories of germplasm of agricultural significance, but 
there  is  an unmet need for the  funding of research 
associated with in situ conservation of germplasm in 
developing  countries.  ACIAR  seems  best placed  to 
take up !his role as, among relevant Australian govern-
ment  agencies,  ACIAR  has  both  the  technical  and 
fmancial  resources  for  undertaking  this  aspect  of 
Australia's obligations under the Convention. 
Recommendation 12 
That  in  allocating  funds  to  the  International 
Agricultural Research  Centres  (I  ARCs),  ACIAR 
give  consideration  to  funding  projects  in  devel-
oping  countries  involving  research  associated 
with the conservation of  germplasm,  including in 
situ  conservation,  so  that  the  international  re-
search  community  may  be  more  likely  to  be 
granted continued access to endemic germplasm. 
IARCs  are  actively  embracing  biotechnology  and 
their projects  and programs need to  be  co-ordinated 
with those of ACIAR's so  that there is no duplication 
of research effort. 
Recommendation J3 
That  ACIAR  be  aware  of the  programs of the 
IARCs  and  of new projects,  including  biotech-
nology projects, so that there is no duplication of 
research effort, but a complementarity is achieved 
to add value to the work of  IARCs. 
Training and Capacity-Building 
All  ACIAR's  partner countries  with  any  significant 
biotechnology research capability have identified the 
lack of trained personnel, research infrastructure and 
expertise as  the major constraint in their biotechnol-
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ogy programs. The most important role that ACIAR 
can play in assisting biotechnology research in devel-
oping  countries  is  capacity  building  and  training. 
Australia is well placed to fulfil this role because of 
its strengths in the quality of its scientists and their 
expertise. Australia can also offer advice and training 
on biosafety assessment. In the area of biotechnology 
training,  there  are  a  number  of  other  players  in 
AClAR's  geographic  mandate  countries,  and  it  is 
important not to duplicate courses but to add value to 
existing courses. 
Recommendation I4 
That ACIAR consider funding Australian experts 
as  resource  persons  in  biotechnology  training 
programs and courses organised by other donors 
in  the  region when they  meet ACIAR's training 
objectives. 
There  appears  to  be a  lack of in  situ  short courses 
within  existing  research  institutions  in  developing 
countries, although this the best way of building bio-
technology  capacity  in  the  long  term.  As  biotech-
nology skills  and training  are  generic in nature and 
transferable,  they can be applied to  any commodity. 
There is a need to fund such courses from funds which 
are not necessarily project-related. The most success-
ful outcomes from biotechnology arise from incorpo-
rating  biotechnology into  existing research programs 
in partiCUlar commodities. 
Recommendation 15 
That  in fulfilling  its  capacity-building  mandate, 
ACIAR give consideration to funding short in situ 
courses in selected institutions in partner count-
ries, which can serve as regional centres of  excel-
lence, in order to develop and integrate biotechno-
logy capability into the existing research strengths 
of institutions in partner countries.  Such courses 
should include the capability to assess the safety 
of  work with genetically manipulated organisms. 2. Introduction 
THE  OFFICB  of Technology  Assessment  of the  US 
Congress  definition  for  biotechnology  has  been 
quoted and used in World Bank pUblications on bio-
technology as  'any technique that uses living organ-
isms, or substances from those organisms. to make or 
modify a product, to improve plants or animals, or to 
develop microorganisms for specific uses'. 
For the  purposes of this  paper. this  definition is 
too broad, as it encompasses all traditional biological 
research. It is more useful to think of  biotechnology as 
a  bundle of more  recently  developed  technologies. 
which have allowed  scientists either to  achieve  the 
same outcomes  faster,  or  to  achieve new outcomes 
which would have been very difficult to achieve. if at 
all.  without  the  use of biotechnology.  The technol-
ogies are diverse,  and not necessarily more sophisti-
cated, although, on the whole, more expensive equip-
ment and reagents are involved. As biotechnology is a 
means to  an  end, not an end in itself, it is useful to 
think of biotechnology as a set of tools developed in 
the last 20 years. 
In the  World  Bank  publications  cited,  biotech-
nology is thought of as  a continuum of technologies, 
ranging  from  long-established  conventional  tech-
nology through to genetic engineering. This concept 
is often used, particularly in official US documents, to 
show  that  biotechnology  need  not  require  special 
regulations since it is simply an extrapolation of past 
technologies. Biotechnology may include technologies 
which  represent  a  continuation  of  traditional  out-
comes, but it  also makes possible new combinations 
and duplications of genetic material which cannot be 
achieved by traditional means, such as making genetic 
combinations  with  genes  originating  from  widely 
separated  taxa.  or multiple  cloning  of animal  em-
bryos.  While  biotechnology  may  represent  a  con-
tinuum,  it is  also  a  departure  from  what might  be 
achieved with traditional technologies. 
The range of technologies that biotechnology en-
compasses are described in the next chapter. and the 
list (see next chapter for explanations) includes: 
monoclonal antibodies. gene probes,  and genetic 
amplification and mapping technologies; 
recombinant  DNA  technology,  use  of  vectors, 
gene libraries. and cloning in bacteria; 
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modern tissue culture techniques, embryo rescue 
and wide crosses; 
anther  culture,  clonal  micropropagation,  and 
somaclonal variation; 
agroinoculation,  'biolistics', tissue culture trans-
formation in plants; 
embryonic stem cell technologies. multiple clon-
ing. nuclear transplantation and transgenesis; and 
site-directed mutagenesis or recombination, •  anti-
sense' technology. 
The list of new technologies is growing year by year. 
In this paper,  it will  not be possible  to  explain  all 
these  technologies.  and  the  interested reader  is  di-
rected to recently-published biotechnology texts, or to 
joumals in relevant disciplines. 
For ACIAR.  knowledge  and  appreciation of the 
scope, implications, capabilities and limitations of the 
technologies are important in assessing whether or not 
to  incorporate them in particular projects. It is there-
fore  essential  for  Research  Program  Co-ordinators 
(RPCs)  to  develop  and  enhance  this  appreciation. 
With regard to increasing the collective knowledge of 
ACIAR's scientific staff of particular biotechnologies 
being used in various fields.  AClAR could consider 
the following options: 
initiate  a  series  of in-house  technical  seminars 
where  scientists  are  invited  to  present  biotech-
nology development~ in their disciplines; 
acquire  the  knowledge  by  means  of a  suitable 
appointment; 
promote  in-service refresher  courses  in research 
ins ti tutions. 
While the options need not be mutually exclusive, and 
may be  appropriate at  various times depending upon 
the inclinations of RPCs, as  a minimum, if  RPCs are 
to embrace biotechnology in their own program areas, 
they would nced to have a theoretical appreciation of 
what new methods are being developed and how the 
techniques  can  meet  the  objectives  of  their  own 
program. 
Recommendation 1 
That ACIAR invite working scientists from 
different disciplines to explain new developments 
in biotechnology in a series of in-house technical 
seminars. 3. Biotechnology Applications in 
ACIAR's Research Program Disciplines 
Crop Sciences Program 
RECENT developments in plant bioteclmology have in-
volved the transformation by recombinant DNA tech-
nology  [1]  of a  range  of plants.  The  list of crop 
species that can be genetically engineered has grown 
daily since the first tobacco and petunia plants were 
transformed  in  1983.  Wheat is  the  most significant 
crop to be transformed and this was achieved in 1992. 
Transformation  of dicotyledons  is  now  routine, 
and  is  achieved  by  the  use of the  crown  gall  bac-
terium,  Agrobacterium  tumefasciens,  as  a  vector  to 
carry the gene of interest into a plant cell. A tumefa-
sciens transfers a portion of its large plasmid [2], Ti, 
into the chromosomal DNA [3] of the plant. The DNA 
transferred causes gall formation. It is possible simply 
to insert the gene of interest into the Ti plasmid, or by 
using a binary vector, where the foreign DNA is carried 
on  a second plasmid, to transform tissue culture cells. 
Since  the  crown  gall  organism  is  a  pathogen  and 
causes  crown  gall  disease,  the  cancer-causing  genes 
are first eliminated from the Ti plasmid which is cap-
able of entering the plant cell and integrating into the 
genome, without the gall-inducing oncogenes. 
Successful transformation invariably involves the 
development  of a  tissue  culture  system  which  can 
regenerate the  whole plant,  a scoring system so  that 
the transformed cell can be identified (usually achiev-
ed  by  means  of an  antibiotic  or herbicide  resistant 
marker) and a 'reporter' gene (such as  the luciferase 
gene)  so  that  the  tissues  expressing  the  introduced 
gene can be identified, once the  transformed cell re-
generates into the whole plant. 
The transformation of monocotyledons has  been 
more  difficult  as  A.  tumefasciens  does  not  infect 
monocotyledons, but is  achieved by means of 'shoot-
ing' pure DNA  of the  isolated gene of interest  into 
meristems or tissue culture by means of a gene gun-
'biolistics', or by injecting the vector, A. tumefasciens, 
with  the  gene  of interest using  a  'gun', a  teclmique 
called  'Agroinoculation'.  'Biolistic' methods involve 
the acceleration of small metal particles (gold or tung-
sten) coated with DNA to penetrate plant cell walls. 
Transformation  experiments  can  achieve  tradi-
tional plant breeding goals in a more rapid and specific 
way  than  by  the  use  of traditional  crossing  experi-
ments, and they can also achieve novel combinations 
of genes  and  new  genotypes.  The incorporation  of 
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genes  from  other uttrelated organisms,  such as  ani-
mals and invertebrates, is not achievable by any other 
technique. 
Use of embryo rescue [4]  and sophisticated tissue 
culture teclmiques has enable genomes from different 
plant farnilies or more distantly related plants, to  be 
crossed-'wide  crossing'.  Other  important  uses  of 
biotechnology are the use of DNA and RNA [5]  se-
quences as probes for  detecting the presence of part-
icular  sequences,  and  genetic  mapping  technology 
using  restriction  enzymes  (which  cut  the  DNA  at 
specific sequences) and comparing the lengths of frag-
ments generated on polyacrylamide gels - restriction 
fragment length polymorphism (RFLP). 
Biotechnology has been applied to crop plants to 
achieve the following: 
pest resistance--BT cotton, potato with coat pro-
tein gene of potato leaf virus, peanut with peanut 
stripe virus coat protein gene; 
herbicide  resistance--herbicide  resistant  cotton, 
lupins; 
higher yields-potato with cytokinin gene; 
elimination of toxins---canola, tomatoes; 
novel  characteristics-blue  colour  in  roses  and 
carnations; 
reproductive isolation-male sterile canola; 
biological control of diseases-genetically engin-
eered bacteria for  control of crown gall  in  stone 
fruit,  'take-all'  disease  in  wheat,  and  bacterial 
wilt; and 
tolerance  to  abiotic  factors-salt,  drought,  cold, 
frost tolerant plants. 
See  Appendix  1 for  the genetically  manipulated or-
ganisms  developed  and  trialed  in  Australia.  Some 
applications,  such  as  the  alleviation of poverty,  sus-
tainable production and ensuring global food security, 
are more relevant to  ACIAR's corporate values, than 
others. Pest-resistant transgenic crops lose their effec-
tiveness once resistance  in  pest populations develop 
and should only be deployed as part of an  integrated 
pest management strategy. Plants with herbicide resis-
tance genes (used as a selection marker, so that herbi-
cides can be  used  to  kill  the cells without the trans-
gene) require the use of specific herbicides which may 
result in  increasing  input costs for  the farmer,  while 
constructs such as  blue roses appeal to  a very  small 
wealthy market. Reproductive isolation may be a use-
ful  management  tool  under  some  agronomic  condi-
tions,  for  example to  prevent outcrossing of a  trans-
gene which may be a problem when expressed in wild relatives.  However,  by and large,  reproductive  iso-
lation would secure for the company developing the 
product, a dependent market for the continued supply 
of  seed. 
ACIAR's  Crop Sciences Program could support 
applications in priority commodity crops  to increase 
yields, to  aChieve pest and disease resistance, and to 
achieve abiotic tolerance, and assign a low priority to 
applications such as herbicide resistance and to repro-
ductive  isolation.  However,  the  value  of particular 
applications  to  the  objectives  of the Crop Sciences 
Program would need to be assessed on a case-by case 
basis. 
Animal Sciences Program 
Technological developments  in  animal research have 
been  so  rapid,  particularly  in embryo  manipulation 
technologies,  that no single publication containing a 
description of all the available techniques  appears to 
exist.  Developments  in  embryo  technology  include 
the  ability  to freeze  and to store totipotent [6]  stem 
cells  derived  from  early embryos,  and  to  reimplant 
these into pseudo-pregnant animals  [7]  and again go 
through another round of harvesting of stem cells  at 
the  blastocyst  stage.  This  quickly  leads  to  the  col-
lection of many genetically-identical stem cells,  and 
thus  to  multiple cloning  of a  single genotype  on a 
scale not previously achievable.  Replacement of the 
nucleus of a totipotent cell with another with a desired 
genotype gives this powerful technique greater flexi-
bility. 
Transgenic  technology  allows  for  the  microin-
jection of pure DNA of a particular gene from  any 
source into  the fertilised egg or into stem cells. This 
generally results in random mUltiple-copy insertion of 
the  construct  into  the  genome  at  a  low  frequency. 
More sophisticated  technology  using  retroviral  vec-
tors [8]  with genetic material containing  flanking se-
quences  to  the proposed site of insertion, will allow 
targeted insertion by  homologous recombination [9]. 
Gene  function  can  be  disrupted  using  'knock  out' 
technology where a functional gene is  replaced by a 
defective one, or by the use of 'antisense' technology 
[10].  Successful transgenesis and expression requires 
the  use  of suitable  promoters  [11]  which  can  be 
triggered by external factors  (e.g.  metals in the diet) 
and a selection marker generally based on drug resis-
tance. Research on the manipulation of sperm (which 
is easier to  harvest and available  in quantity) rather 
than eggs, has just begun. 
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Immunological developments are also proceeding 
apace. and a number of veterinary diagnostic kits a-
rising from recombinant DNA technology are already 
on the market. Vectors for carrying antigens based on 
attenuated  animal  viruses-fowlpox  for  poultry 
disease, vaccinia, and others, are being developed as 
vaccines against viral and bacterial diseases. The devel-
opment of vaccines  against  multicellular parasites  is 
taking longer, either because it is  difficult to  identify 
the immunogenic antigens concerned, or more funda-
mentally,  because infection does  not necessarily pro-
duce  immunity  against  superinfection.  Nevertheless, 
there is a cattle tick vaccine on the market which does 
reduce the parasite burden as  well as other prototype 
vaccines.  The  manipulation  of  the  hormones  and 
'immunogenetics'--developing vaccines which either 
carry the hormone or its receptor protein--can mod-
ulate fertility, lactation and muscle enhancement. 
Hence, biotechnology could be applied in all areas 
in the ACIAR's Animal Sciences Program: 
productivity--enhancing growth rate, earlier wean-
ing,  enhancing  milk  production  and  muscle 
growth; 
nutrition-transgenes  for  biosynthetic  enzymes 
for the endogenous production of particular amino 
acids  e.g.  cysteine,  improving  nutritive value of 
pasture grasses, lupins etc, removing toxins from 
feedstuffs, gut micro flora manipulation; 
health-vaccines against viral  and  bacterial  dis-
eases, diagnostics; 
stock-multiple  cloning,  increasing  litter  size, 
improving  desirable  characteristics  and  deleting 
undesirable genes; and 
management  practices-manipUlating  'oestrus', 
eliminating taints in meat so that animals need not 
be castrated. 
A  serious  constraint  in animal  biotechnology  is  the 
public  acceptability  of  the  technology  and  of  the 
resulting  food  product,  and  ethical concerns  arising 
animal  experimentation  in  general,  which  will  be 
discussed later in  this paper. Only one proposal for  a 
transgenic  animal,  a  transgenic  pig  with  porcine 
growth  hormone  gene,  has  been submitted  for  bio-
safety assessment in Australia, but no decision has yet 
been taken. 
ACIAR's  Animal  Sciences  Program  could  give 
priority  to  aspects  which  are  relatively  uncontro-
versial,  such  as  the  development  of  vaccines  and 
increasing the nutritive value of feedstuffs, and assign 
low priority to animal transgenesis. Postharvest Technology Program 
The same range of technologies described in the Crop 
Sciences sub-section, is applicable in the postharvest 
area.  Biotechnology  can  achieve  the  objectives  of 
reducing  losses  due  to  postharvest  diseases  and  of 
extending  shelf-life.  'Antisense'  technology  (DNA 
with the sequence of the gene in reverse orientation) 
has  been  used  to  block  the  ethylene  biosynthetic 
pathway,  or  an  enzyme  which degrades  cell  walls, 
thus  delaying  ripening  of fruits  and  vegetables.  At 
least one such product is available in the marketplace. 
Tropical fruits  are more prone to  rapid deterioration 
than temperate fruits, so the problem of delaying rip-
ening is more urgent for these products. 
The incorporation of the coat protein of gene of a 
virus  provides  resistance  to  infection,  although  the 
mechanism  for  this  effect is  not completely  under-
stood. Another strategy which may be useful to pur-
sue,  is  to  delay  the  onset of disease  symptoms  in 
infected fruit by means of manipUlating host defence 
mechanisms. 
Postharvest applications include: 
delayed ripening of vegetables and fruits, such as 
the Flavr Savr tomato, now on the US market; 
biological control of post harvest diseases-stem 
rot control; 
fermentation characteristics-increasing the sugars 
which can be used  as  substrates,  making cheese 
starter cultures resistant to bacteriophages; 
flavour  and  taste-genetically engineered sweet-
eners; 
processing characteristics--juice and pulp consis-
tency, change viscosity of tomato pulp; and 
additives for nutritional characteristics--e.g. lysine 
or methionine biosynthetic genes added to cereals. 
One of the technical difficulties is  the limited number 
of fruit species for which tissue culture systems have 
been developed. Other difficulties relate to regulation, 
and  the  low  customer  acceptance  of  genetically 
engineered  food  products  by  some  sectors  of the 
community. These issues are dealt with in Chapter 6. 
Forestry Program 
Again the same technologies described for crops can 
also be used in forestry. Clonal micropropagation [121 
has  an  important role  to  play  in the  rapid  mUltipli-
cation of relatively rare superior genotypes, e.g. some 
tropical  hardwoods.  As  with  traditional  technology. 
the major objectives in tree breeding are vigour. stem 
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form  and  wood  quality.  For  some  niche  markets, 
genetic engineering applications. include: 
lignin reduction in pulp species; 
cold tolerance to  increase range sites for  species 
e.g. eucalypts; and 
insect or fungal resistance. 
Difficulties  include  the  long  field  testing  period 
required  for  assessment of transgenic  trees,  and  for 
back-crossing  programs,  because  of the  generation 
time of some  species.  As  well,  tissue  culture  tech-
niques  are not sufficiently advanced in  a number of 
important industrial species for  genetic manipUlation 
to be contemplated. 
A  recent  Food  and  Agriculture  Organisation 
(FAO) paper (Haines 1994) predicts that tropical sites 
will  be  most  likely  to  meet  the  predicted  global 
demand for  industrial plantations of 100 million ha. 
and non-industrial plantations of several  100 million 
ha. Biotechnology may be the most promising way of 
meeting these targets. 
Land and Water Resources Program 
The  sustainable  use  of  land  and  water  resources 
includes  the use of microorganisms  as  biofertilisers. 
These fall into the following groups: 
symbiotic  nitrogen-fixing  bacteria.  such  as 
Rhizobia species; 
mycorrhiza-forming fungi; 
phosphate solubilising fungi; 
plant  associated  microorganisms  such  as  endo-
phytes, and free-living root zone microorganisms; 
and 
algal biofertilisers such as Anabaena:. 
Transfer of bacterial nitrogen-fixing genes into plants 
is  some  way  off  in  the  future  because  of  the 
complexity of nitrogen fixing genetics. Rhizobium has 
long  been  the  target  of genetic  manipUlation  and 
recombinant strains which combine good  nodulating 
characteristics with efficient nitrogen-fixing,  and are 
now  available on  the  market.  However,  in  practice, 
one of the difficulties is  to  get an efficient strain to 
replace endemic strains in the soil. Work underway at 
present  enhances  the  competitiveness  of the  intro-
duced strain. Strategies include: 
making the strain resistant to some agent that kills 
other Rhizobia; 
creating or taking advantage of the 'fit' between a 
specific strain and host species; and 
enhancing  the  likelihood  of the  inoculum  inter-
acting with the host (e.g. by use of flavonoids). Other  applications  for  soil  microorganisms  in-
clude biological control agents  for  diseases  such as 
crown gall, and Australia was the fIrst country to put a 
genetically engineered product on the market for this 
purpose. The possibility of using endophytes [13]  as 
vectors for a whole range of characteristics including 
increasing  yields,  adding  hormones and nutrients,  is 
currently being explored. 
The genetic manipUlation of soil microorganisms 
usually involves using antibiotic resistant markers, as 
selection  involves  killing  non-recombinant  strains 
with  the  antibiotic.  Most of the  antibiotic  resistant 
markers are already prevalent in soil microorganisms, 
but it may be necessary to  asccrtain at the proposal 
stage that the marker does not give resistance to  an 
antibiotic commonly used in veterinary practice. 
Aquaculture Program 
Biotechnology has little relevance to the harvesting of 
wild stocks and  will  not be discussed here, sustain-
ability and management being the main issues for  this 
type of fishing. Over-exploitation is  already a signif-
icant problem globally and  is  rapidly leading  to  the 
depletion of marine resources particularly for devel-
oping countries which depend on marine resources for 
food.  Aquaculture  provides  the  best  hope  of sus-
tainable production to meet increasing demand in the 
long term. 
Biotechnology  can  be  applied  to  contained 
aquaculture systems, but the use of  such technology is 
in its  infancy.  Among  the  applications  being  deve-
loped in Australia. North America and in Europe, are: 
hypophysation-induction  of  spawning  by  in-
jecting pituitary gland extracts into mature fishes; 
sex  reversal  or reproductive  isolation-adminis-
tration of hormones; 
formulation  of  feed-culture  of  bacteria  or 
microalgae; 
gynogenesis (production of all female offspring). 
triploidy  and  tetraploidy-with  more  than  the 
normal complement of chromosomes; 
transgenesis-growth  hormone,  insulin,  vitel-
logenin, anti-freeze protein genes; 
vaccines  and  diagnostics--e.g. monoclonal  anti-
bodies for the detection of Vibrio species; and 
production  of biological  products  from  algae-
beta..carotene from Dunaliella. 
Developing countries are already using hypophysation 
and sex reversal. Diet formulation and diagnostics are 
at the development stage. However, at present. genetic 
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engineering  is  exclusively  being  undertaken  in 
developed  countries.  Unlike  the  more  limited  re-
sponse seen in mammals,  transgenic IlSh  with extra 
piscine growth hormone genes grow many times their 
usual size, provided feed is not limited. This has been 
demonstrated dramatically with Pacillc salmon at the 
government agency, 'Fisheries and Ocean', Canada. 
An analysis of the needs of developing countries 
(Guerrero 1991) identilled the following applications 
as being appropriate for Asian aquaculture: 
genetic  improvement  of  cultured  species  for 
improved  growth.  disease  resistance  and  adapt-
ability to new farming systems; 
development  of low-cost but effIcient  grow-out 
diets  for  cultured  fish  using  locally  available 
foodstuffs and microbiological cultures; 
production of vaccines and monoclonal antibodies 
for  the  prevention  and  control  of bacterial  and 
viral diseases; 
development of drugs and other biotechnological 
products from marine organisms. 
One of the problems of the genetic engineering of fish 
is  the  difficulty  of  maintaining  strict  containment 
conditions  to  prevent  the escape of transgenic  fish, 
eggs, fry and gametes. If a net is used, the mesh size 
should  be  small  enough  to  prevent  the  escape  of 
gametes  and  strong  enough  to  withstand  large 
pressures.  which  makes  this  impracticable.  Contin-
gencies  such as  flooding  and run-off make contain-
ment a serious problem. The production of sterile IlSh 
may be a early and appropriate objective of genetic 
engineering. 
Agricultural and Natural Resource Economics 
Program 
As  biotechnology comprises a range of diverse tools, 
its impact is the same as that arising from traditional 
technologies. It can decrease the cost of inputs. lower 
production  costs,  and  increase  output for  the  same 
input costs. as well as increase the quality and value of 
crops.  However,  benefits  will  only  arise  if  the 
technology  is  applied  appropriately  and  adopted. 
Biotechnology can also be capital intensive, raise the 
cost of the final product, and can increase the cost of 
labour by the use of skilled personnel. 
It may be useful to  think of the economic impact 
of biotechnology in time-frames. In the short term, as 
laboratories are investing in equipment and scientists 
are being trained, the impact on costs could be signif-
icant. In the medium term. biotechnology will be used as  a  substitution  technology  to  produce  the  same 
products  more  efficiently,  and  therefore,  could  in-
crease profits and returns to farmers. In the long term, 
it has the potential to  revolutionise agricultural  pro-
duction systems by breaking through present produc-
tivity ceilings, e.g. reducing usage of chemical inputs, 
farming  of  marginal  agroecological  zones,  maxi-
mising sustainability of renewable resources, use of 
superior genotypes  in terms  of yields,  reduction of 
waste.  pest and  disease resistance,  and tolerance  to 
abiotic conditions. The result  in  the  long run is the 
more  efficient  use  of natural  and  agricultural  re-
sources. 
Options 
The  present  ACIAR  portfolio  of  on-going  and 
completed projects  is  seen  in  Appendices  2  and  3 
(information  in  these  appendices  as  at  May  1995). 
Bioteclmology  comprises  a  low  proportion  of 
AGAR's 300 completed projects and over the last 12 
years  only  14  have  used  biotechnology.  This  low 
proportion  is  gradually  increasing  and  a  higher 
proportion of proposed projects plan to  use biotech-
nology.  It appears that there is  no deliberate attempt 
by  the project leaders or RPC's to promote the use of 
bioteclmology  in  projects  and  its  use  is  purely 
incidental. Decisions on methodology should be based 
on  an assessment of the effectiveness and efficiency 
of  the  method  concerned  to  achieve  project  and 
program objectives. within the limitations of facilities 
and  expertise  available  in  particular  developing 
countries.  Bioteclmology  may  be  the  appropriate 
methodology in  some projects and can enhance and 
complement traditional methods. 
ACIAR could contemplate the following options: 
do not incorporate bioteclmology into projects; 
have a separate bioteclmology program; 
include  bioteclmology  projects  in  all  programs 
where it is  the most effective means  of meeting 
the project objectives. 
Not using  biotechnology at all  is  not a viable long 
term option. as opportunities for successful outcomes 
will pass ACIAR by as institutions in Australia and in 
ACIAR's  partner  countries  increasingly  use  new 
technologies.  Having  a  separate  bioteclmology  pro-
gram would deny its generic nature. and shut out its 
potential  to  contribute  to  the  objectives  of  all 
ACIAR's programs. 
It is  thought,  even  by pessimists,  that biotech-
nology offers the best hope of raising productivity and 
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meeting global demands for food in the future (rribe 
1994). It can be  seen from  the  above  analysis  that 
bioteclmology  has  the  potential  to  contribute  to 
ACIAR's  program  objectives.  The  rational  option. 
therefore, is to incorporate biotechnology into projects 
in  all  programs.  Since  biotechnology  provides  a 
powerful set of tools, it can achieve objectives in all 
program areas. 
The application of  biotechnology is most likely to 
be successful when integrated into traditional species 
improvement breeding programs for the species con-
cerned, particularly where tissue culture methods and 
micropropagation techniques are advanced. 
Recommendation 2 
As biotechnology provides a set of tools to achieve 
research objectives, It has the capacity to 
contribute to all program areas, and could be 
Integrated into projects where Its use is tbe best 
way to achieve the objectives of the project. It  can 
complement traditional research methods, and is 
most successful when augmenting pre-existlng 
research strengths in the partner country. 
Endnotes on Chapter 3 
1.  Transfer  of genetic  material  between  organisms 
using a vector so that the resulting organisms carries a 
segment of genetic  material  from  another  organism 
joined to its DNA. 
2.  A small, extrachromosomal,  circular DNA that is 
used to transfer genes from one organism to another. 
3.  Deoxyribose nucleic acid,  the composition of the 
polymeric molecule that carries the  'blueprint' of the 
organism. 
4. The process in plant breeding whereby tissue from 
young  embryo  plants  is  excised  and propagated  in 
vitro for subsequent growth as differentiated plants. 
5.  Ribonucleic  acid,  the  chemical  composition  of 
some viruses and  'messenger' in all cells carries the 
genetic code from the nucleus to the cytoplasm where 
proteins are synthesised. 
6.  Undifferentiated embryonic cells with the potential 
to develop into the whole multicellular organism. 
7.  Simulating  the  physiological  characteristics  of 
pregnancy in animals by the use of hormones. 
8.  Viruses with RNA genomes which are synthesised 
into DNA by the cellular enzymes, once they infect a 
cell, and become integrated into the DNA of the cell. 
9.  Exchange of DNA between two genomes at points 
where the sequences are identical. 10. Introducing genetic material into the cell with the 
gene concerned in reverse orientation (so that the code 
is read backwards) so that normal reading of the gene 
synthesis of the protein is disrupted. 
11.  Sequences  of the  DNA  occurring  before  a  se-
quence coding for a protein which  act a  'switch' to 
turn on expression of the gene. 
12. Propagation in vitro  from  undifferentiated callus 
tissue of a plant to give multiple plantlets. 
13.  Organisms  which  live  in  the  vascular tissue of 
higher plants. 
10 4. Australia-Strengths, Weaknesses, 
Opportunities and Constraints 
Strengths 
IT  is  beyond  the  scope  of this  paper  to  describe 
Australia's  biotechnology  research  strengths  and 
weaknesses  in  any  detail.  Agricultural  research,  in-
cluding biotechnology, has historically been strong in 
terms of funding,  perfonnance and outputs. Australia 
embraced  biotechnology  after  the  discovery  of 
restriction endonucleases was made in the early 1970s 
and  after  then,  every  graduate  from  any  Australian 
university in the biological sciences has been through 
courses  which  incorporate  the  latest  techniques  in 
biotechnology.  Australian  commissioned  organisa-
tions in ACIAR's projects including CSIRO's agricul-
tural divisions, universities and state agricultural insti-
tutions, have pursued and applied biotechnology in all 
fields of research. 
More  recently,  the  Australian  Government  has 
established Cooperative Research Centres (CRCs)  to 
bring together CSIRO, universities, state agencies and 
industry to enable a 'critical mass' of research effort to 
be broUght together, so  that commercial products may 
be developed. The CRCs applying biotechnology (and 
their contact details)  relevant  to  ACIAR's programs 
are listed in Appendix 4,  and are a good indicator of 
Australia's research strengths. Although the CRCs are 
directly  concerned  with  developing  products  for 
Australia rather  than for  developing  countries,  CRC 
managers  will  be  able  to  put  ACIAR  Research 
Program Coordinators in touch with particular scien-
tists  and  institutions  with  strengths  in  the  areas 
concerned,  and  thus  serve  a  useful  networking 
function. 
To  complement its strong research infrastructure, 
Australia  also  has  good  information  dissemination 
mechanisms  and  extension  services  to  farmers  to 
deliver the products and services arising from agricul-
tural research. 
Australia has strengths in the biosafety assessment 
of genetically  manipulated  organisms  and  its  non-
statutory monitoring system was established in  1975 
with the pUblication of the first set of national guide-
lines  for  recombinant DNA work  by  the  Australian 
Academy  of  Science  Committee  on  Recombinant 
DNA. These guidelines preceded the US  Guidelines. 
The monitoring system has gone through a number of 
incarnations and the  Genetic Manipulation Advisory 
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Committee (GMAC)  in  the  Commonwealth  Depart-
ment of Administrative Services now overviews gene-
tic engineering in all Australian institutions. 
In  1990,  the  Minister  for  Industry,  Technology 
and Commerce submitted a reference to  the House of 
Representatives Committee on Industry, Science and 
Technology to  examine the issues concerning genetic 
engineering and the adequacy of the present advisory 
system.  The  Inquiry  Report,  published  in  1992, 
recommended the establishment of a new legislative 
authority  with an expert committee  like  the  present 
GMAC,  reporting  to  it.  Although  the  Government 
accepted  the  thrust  of the  recommendations  of the 
Inquiry,  there have been difficulties in getting agree-
ment  from  all  the  states  for  a  national  legislative 
system to approve releases of genetically manipUlated 
products into the environment. 
Another of Australia's strengths is the quality of 
its  tertiary  education  system,  which  has  attracted 
students  from  its  regional  countries  especially  from 
Southeast Asia,  since the days of the Colombo Plan 
Scholarships. The university system was expanded in 
the 1980s, and some of the newer universities did not 
have a research tradition, consequently the quality of 
biotechnology  courses  in  some  universities  is  vari-
able. 
Australia  has  an  industrial  patent  legislation 
which covers living organisms, and  is  a signatory to 
the  Union of Convention for  the Protection of New 
Varieties  of  Plants  (UPOV)  and  the  Biodiversity 
Convention. 
Weaknesses and Constraints 
Australia's  weaknesses  in  biotechnology  tend  to  be 
the same as its weaknesses in all other research fields. 
These  include  the  low  proportion  of private  sector 
investment  in  research  compared  to  other  OECD 
countries, the lack of an industry sector of sufficient 
size to  take products successfully through the devel-
opment  and  marketing  phases,  through  regulatory 
hurdles  and  on to  the  supennarket shelves,  and  the 
relatively  low  proportion  of  strategic  and  applied 
research  compared  to  other OECD countries.  These 
issues  have  been  the  subject  of many  Government 
reports. 
Although  Australia  has  expertise  in  molecular 
biology, and in the agronomy of its main agricultural 
commodity products-e.g. wheat,  cotton,  sugarcane, 
it has  little  experience with the cultivation of com-
modities which may be of interest to partner countries such  as  rubber,  palmoil  and  some  tropical  fruits. 
Consequently, Australia has much to learn as  well as 
to teach its partner countries in collaborative research 
projects. This is an  important factor in the successful 
application  of biotechnology  to  particular  species. 
Since biotechnology provides a set of tools, expertise 
in the species to be transformed as well as expertise in 
the  use  of the  tools  themselves,  is  necessary  for  a 
successful outcome. 
Constitutionally, Australia is a federation of states 
which have responsibility for delivery of agricultural 
services,  but  the  research  funding  system  is  plural-
istic,  comprising  Commonwealth  organisations  like 
the CSIRO,  State Departments which also  undertake 
research, commodity-based Boards and Corporations. 
as  well as  strong interest groups such as  the National 
Farmers  Federation.  Consequently,  the  nation  as  a 
whole has  a diversity of funding  sources and policy 
advisory  mechanisms  which together act to  balance 
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any distortions, or tendencies to  skew agriCUltural re-
search in any particular direction. Unlike the centrally-
directed biotechnology programs of ACIAR's partner 
countries,  Australia's  biotechnology  projects  are 
funded from a diverse range of sources, with differing 
priorities. 
Opportunities 
Australia  has  negotiated  Science  and  Technology 
Agreements with a number of developing and devel-
oped countries in the Pacific region in order to estab-
lish cooperative science and  technology ventures. In 
the  area of biotechnology,  Australia's strengths  is in 
its  research  capacity,  scientific  expertise  and 
regulation. 
In  sununary,  Australia  can  offer  research  and 
policy  expertise,  and  a  variety  of biotechnological 
tools which underpin all biotechnology research, train-
ing and biosafety asse.<;sment, to its partner countries. s. Partner Countries-Strengths, 
Weaknesses and Constraints 
India, China and Southeast Asia 
BIOTECHNOLOGY  can  only  be  successfully  applied 
within existing research programs.  In order to  carry 
out  collaborative  research  involving  biotechnology, 
the partner country needs to have an existing research 
capacity.  Of ACIAR's partner countries in its  tradi-
tional  geographic  mandate,  those  which  have  any 
significant biotechnology capability are: 
China (Appendix 5); 
India; 
Indonesia (Appendix 6); 
Malaysia (Appendix 7); 
Pakistan; 
Philippines (Appendix 8); 
Thailand (Appendix 9); 
Vietnam (Appendix 10). 
The region comprising the Indian Subcontinent, China 
and  Southeast Asia is  the most important region for 
Australia  in terms  Official  Development  Assistance 
(ODA)  expenditure.  Expenditure for  Southeast Asia 
alone exceeded that for Papua New Guinea in the 93-
94 AusAID budget for the first time. at $365 million. 
Among the countries in this area, there are strengths in 
traditional commodity research, as listed below: 
China--rice. pigs. wheat. tobacco, maize; 
India--rice, pulses, milk, wheat, fuelwood; 
Indonesia--rice.  soybean.  garlic,  potato. banana. 
timber; 
Philippines--coconut,  rice.  bananas.  maize. 
fisheries; 
Malaysia--rubber, oil palm, cocoa, pepper, timber; 
Thailand-rice,  cassava.  ornamental  flowers, 
tropical fruits, fisheries; and 
Vietrtam--rice,  maize,  cassava.  fruit,  root  and 
tuber crops. 
ACIAR's  Country  Managers  were  asked  to  supply 
information relating to  the country strengths in  infra-
structure  and  the  research  activities  conducted  in 
them.  As  well,  information  on  programs,  policies, 
biosafety and intellectual property rights (IPR) status 
was also sought. Appendices 5-10 present this  infor-
mation for China. Indonesia, Malaysia. the Philippines 
and  Vietrtam.  Where there was no country manager, 
the information  was  derived from  Sasson 1993,  and 
Komen and Persley 1993. 
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Policies, Programs and BlosaIety Regulation 
In  general,  biotechnology  research  programs  and 
policies have been  centrally funded  and coordinated 
by national governments in all eight countries. 
Chlna  has  drawn  on  the  extensive  research 
capacity  of  the  Chinese  Academy  of  Agricultural 
Sciences (CAAS) by creating the Biotechnology Re-
search  Centre  to  focus  biotechnology  research  in 
CAAS Institutes. The China National Centre for Bio-
technology Development (CNCBD), created in 1983, 
coordinates  all  biotechnology  research  and  devel-
opment (R&D) activities, including training and inter-
national  cooperation.  The  six  main  biotechnology 
research  centres  under  the  CNCBD  are  listed  in 
Appendix 5. 
Biotechnology, among other high-technology, was 
a  priority  area  identified  under  the  863  Program 
(established in March 1986) by the State Science and 
Technology Commission.  Research priorities, with a 
budget of US $20 million, were identified as: 
varieties of plants and animals to  increase yields 
of grain, meat, milk and fish; 
protein engineering and genetic engineering; and 
development of  new drugs. 
China  has  strengths  in  the  area  of  fermentation 
technology and plant tissue culture. There are about 
1000 research units engaged in either tissue culture or 
anther culture work, and this has served as a spring-
board for  the early and rapid development of genetic 
engineering of plants. 
China has no regulatory system for biotechnology 
in spite of having many thousands of hectares under 
cultivation with transgenic crops, mainly tobacco. 
India also  has a centrally coordinated program in 
biotechnology, first established under the Sixth Five 
Year  Plan  (1980-85),  with  the  setting  up  of the 
National  Board  on  Biotechnology  in  1982.  Sub-
sequently, the Board's functions were assigned to the 
Department of Biotechnology (DBT) in the Ministry 
of Science and Technology. Its role is to: 
develop integrated plans and programs in biotech-
nology; 
identify specific R&D programs in biotechnology 
and biotechnology-related manufacturing; 
support biotechnology infrastructure development; 
facilitate the import of biotechnological processes, 
products and technology; 
formulate  biosafety  guidelines  for  laboratory 
research and applications. The DBT has Action Plans where priorities are estab-
lished.  Agricultural biotechnology research is coordi-
nated by the Indian Council of Agricultural Research, 
which funds the infrastructure for agricultural research. 
India  has  a  set  of  Recombinant  DNA  Safety 
Guidelines for research with genetically manipulated 
organisms  and  institutional  biosafety  committees 
within  centres  engaged  in  biotechnology  research. 
These committees  are  guided  by  the  Review  Com-
mittee in the DBT.  As  well,  the  Department of En-
vironment has a Genetic Engineering Approval Com-
mittee for the review of large-scale and field release 
applications. 
There is a national network for biotechnology re-
search in Indonesia comprising of a number of institu-
tions but the primary responsibility for implementing 
agricultural  biotechnology  programs  lies  with  the 
agency  for  Agricultural  Research  and  Development 
(AARD) and its  Central Research Institute for  Food 
Crops (CRIFC). AARD has recently been restructured 
so that each research institute of AARD is confined to 
its  own  mandate commodity,  and  has  established  a 
Research  Institute  for  Biotechnology  in  Bogor.  As 
well,  there  is  a  very  well  equipped  Research  and 
Development Centre for Biotechnology funded by the 
Indonesian Institute of Sciences (LIPI). 
A number of new institutes,  called Institutes for 
the Assessment of Agricultural Technologies (IAATs) 
have  recently  been  created  for  downstream  devel-
opment  and  trialing  of products  from  a  Research 
Institute. See Appendix 6 for a comprehensive list of 
institutions  engaged  in  biotechnological  research 
(biotechnology here is interpreted very widely as  any 
biological research). 
The National Committee for  Biotechnology was 
established  to  implement  biotechnology  policy,  in-
cluding  guidelines  for  regulation  of biotechnology 
and intellectual property rights. At present, there is an 
ad  hoc  committee  comprising  experts  which  is 
summoned by government agencies requiring  advice 
on the biosafety of specific projects. 
Three inter-university centres (lUCs) were estab-
lished in 1985 financed by World Bank loans amount-
ing to US $23 million: 
IUC  for  Agricultural  Biotechnology  at  Bogor 
which  undertakes  research  in  tissue  culture, 
microbiology,  molecular  genetics,  fermentation, 
Rhizobium and mycorrhiza inoculants; 
IUC  for  Industrial  Biotechnology  at Bandung-
microbiology  and  fermentation,  enzyme  tech-
nology, waste water treatment; 
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ruc for  Medical Biotechnology at Gajah Mada 
University,  Jogjakarta-vaccine  production  for 
tropical diseases. 
The IUCs train faculty members from other univer-
sities,  conduct post-graduate research programs  and 
establish links with industry. 
Malaysia has just set up (April 1995) the National 
Biotechnology Directorate in the Ministry of Science, 
Technology  and  the  Environment  with  a  budget of 
100  million  ringgit  over  3  years  for  the  National 
Biotechnology  Program.  The  Directorate  will  take 
over all  the functions of the National Biotechnology 
Working Group, which was established in 1991 to: 
advise  the  government  on  policy  issues  of 
research funding and incentives to industry; 
monitor new developments in biotechnology; 
facilitate  R&D  cooperation  between  research 
institutions and industry; 
establish safety and ethical guidelines. 
The Directorate is  also considering funding a central 
bioprocessing  manufacturing  facility.  Priority 
investment areas of the Directorate include: 
diagnostics, vaccines and other health products; 
plant tissue culture; 
biotechnology of oleochemica1s; 
natural products screening and development; and 
environmental biotechnology. 
Malaysia  has  excellent  agricultural  research  infra-
structure,  with  four  main commodity research insti-
tutes: 
the  Malaysian Agricultural  Research  and Devel-
opment Institute (MARDI); 
the  Palm  Oil  Research  Institute  of  Malaysia 
(PORIM); 
the  Rubber  Research  Institute  of  Malaysia 
(RRIM); and 
the Forest Research Institute of Malaysia (FRIM). 
As  well  as  these  four  agricultural  research centres, 
several plant biotechnology programs are carried out 
in universities, including  the  University of Malaysia, 
the  National  University,  the  Science  University  of 
Malaysia and the Agricultural University of Malaysia. 
The Government of Pakistan has established the 
National  Institute  for  Biotechnology  and  Genetic 
Engineering  (NIBGE)  at  Faisalabad,  affiliated  with 
the Quaid-e-Azam University, Islamabad. NIBGE has 
six research groups: 
plant  biotechnology-plant  genetic  engineering 
for crop improvement; 
biofertilisers-genetic  engineering  of  microor-
ganisms such as Frankia and Rhizobium; biofuels-microbial  conversion  of  biomass  to 
alcohol and methane gas; 
mineral and fossil fuel biotechnology-microbial 
liquefaction of high grade fuels; 
environmental biotechnology-includes bioreme-
diation and biosafety assessment of the environ-
mental release of genetically engineered microor-
ganisms; and 
basic  biology-monoclonal  antibodies  and 
vaccine production. 
NIBGE  has  international  linkages  with  research 
groups in the US and Europe. 
The  Science  and  Technology  Council  of  the 
Philippines. through its  Sectoral Technical Panel on 
biotechnology  identified  the  following  priorities  for 
1991-95: 
coconut tissue culture; 
production of high-value fats from coconut oil; 
human.  animal.  and  plant  diagnostics  and 
vaccines; 
reforestation through tissue culture; 
penicillin production using  locally available raw 
materials; and 
treatment of human waste. 
The  Philippines  also  has  a central national  biotech-
nology  institute-the  National  Institute  of  Bio-
technology  and  Applied  Microbiology  (BIOTECH) 
founded in 1979 to: 
provide  direction  and  support for  biotechnology 
research; 
provide training to support industry; 
provide scientific advice to Government; and 
facilitate  commercial  applications  of  biotech-
nology. 
Stringent biosafety guidelines for case-by-case assess-
ments have been drawn up by the National Committee 
on  Biosafety  (NBC)  established  in  1990.  and  the 
Philippines  has  a  system  of  institutional  biosafety 
committees.  The  NBC  coordinates  other  agencies 
involved with regulations such as quarantine services. 
A  central  national  agency  in  Thailand.  the 
National  Centre  for  Genetic  Engineering  and  Bio-
technology (NCGEB) was established in 1983 to  co-
ordinate  biotechnology  activities  and  supports  re-
search  in  five  laboratories  at  the  universities  of 
Chulalongkorn. Mahidol.  Kasetsart,  Chiang  Mai  and 
the  King  Mongkut  Institute  of Technology.  These 
centre focus on work in: 
tissue culture; 
plant selection and germplasm conservation; 
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biofertilisers; 
pest control; and 
rice. 
A new  Bioservice Unit has been established by the 
NCGEB at Mahidol University. as  a core facility for 
the  common  use of expensive  instruments  such  as 
DNA synthesisers. In 1991. the NCGEB was brought 
under  the  National  Science  and  Technology  Deve-
lopment Agency. 
Thailand has  guidelines  on biosafety drafted  by 
the  Biosafety  Subcommittee  of the  National  Com-
mittee for Science and Technology. 
After much preparation. the Vietnam Government 
in  1994  released  a  National  Strategy  Directive  for 
Biotechnology  Development.  The two  goals  of the 
strategy were: 
the establishment of research facilities. including 
the foundation of the Institute of  Biotechnology in 
the Centre for  National Science and Technology. 
and laboratories at universities-see Appendix 10 
for a complete list; and 
the  establishment of the National Biotechnology 
Program  under  the  National  Council  for  Bio-
technology-see Appendix 10 for priorities of the 
program. 
Funding for the projects undertaken in the facilities is 
largely from US official development aid. 
Weaknesses and Constraints 
The following  constraints  were identified in various 
papers  at  a recent International Service for  National 
Agricultural  Research  (ISNAR)  Conference  titled 
'Turning  Priorities  into  Feasible  Programs' -a re-
gional seminar on planning priorities and policies for 
agricultural biotechnology. 25-29 September. 1994: 
human  resource  constraints  including  lack  of 
technical knowledge and research experience; 
uncertain or inadequate proprietary protection for 
biotechnology (See Appendices 5-10); 
lack of awareness of biosafety assessment proce-
dures. or inappropriate regulations; 
inadequate  communications  and  extension  net-
works to disseminate results; 
weak science base at tertiary institutions; and 
the lack of infrastructure and capital investment. 
All  the  developing  countries  are  either  actively 
examining  proprietary  protection  for  biotechnology. 
or  are  making  the  protection of plants.  animals  and 
microorganisms  explicit  in existing  IPR  legislation. 
particularly  industrial  patent  legislation.  post  the Uruguay GAIT round. At the present time, the status 
of IPR protection for biotechnology is unclear in most 
developing countries, with the exception of China and 
Thailand  where  biotechnology  is  protected  under 
recently amended patent legislation. Even in the case 
of China. plant and animal varieties are not explicitly 
covered. 
Some of these constraints can only be addressed 
by the  govemment of the developing  country  con-
cerned, using IPR legislation, but developed countries 
can play a role in overcoming others. The subsequent 
sections  of this  paper  deal  with  ACIAR's  role  in 
overcoming  constraints  relating  to  IPR,  biosafety, 
training and capacity building. 
Other regions 
Countries of the other regions in ACIAR's geographic 
mandate (Latin America.  the  Pacific  and  Africa) do 
not  have  any  significant  biotechnology  research 
capacity,  and  still  require  assistance  in  setting  up 
facilities  and  training  personnel  for  traditional 
research in specific commodities. 
Some  African  countries  such  as  Zimbabwe, 
Kenya and Tanzania are developing a biotechnology 
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capability,  as  are  some countries in Latin America. 
However,  the  presence  of  other  donors  in  these 
regions (European countries in Africa and the US  in 
South  America)  makes  it less  important  for  Aust-
ralia's  Official  Development Assistance  (ODA)  and 
this  is  reflected in Australia's ODA expenditure for 
these regions. Countries of the sub-Saharan region, in 
addition,  suffer from political instability,  the lack of 
any  infrastructure  (e.g.  communications,  extension 
and distribution networks) and serious degradation of 
all natural resources. These countries  would not,  in 
general. be suitable partners for biotechnology collab-
oration (except where collaboration involves an inter-
national agricultural research centre, IARC). 
Some IARCs are located in these regions and are 
dealt with separately  in  Chapter 7 of this  report. In 
general IARCs are well resourced and have access to 
the latest technology and expertise from the interna-
tional  scientific  agricultural  community.  They  can 
thus  serve  as  catalysts  and  facilitate  biotechnology 
research  in the  country  in  which  they  are  located. 
They  can also  provide  expert  technical  and  policy 
advice to  country governments on issues such as  the 
biosafety of  particular projects. 6. Bilateral Policy Issues 
TlUS  chapter deals with issues arising from the use of 
biotechnology  in  ACIAR's  bilateral  programs.  Al-
though these issues are associated with biotechnology, 
they  are not confmed to  it,  and can arise from other 
kinds of research. Nevertheless, biotechnology accen-
tuates  them.  To  address  these  issues,  appropriate 
internal  ACIAR policies  and procedures  which may 
need to be addressed, are identified. 
Issues associated with the application of biotech-
nology in bilateral programs include the assessment of 
the  feasibility-of-concept  of a  proposed project,  the 
equitable  and appropriate  distribution of intellectual 
property rights and biosafety. 
In-house review 
During  the  development  of new  project  proposals, 
ACIAR projects go through in-house review at each 
of  the  first  three  phases  of  project  development. 
Comments  are  sought  from  all  scientific  and  econ-
omic staff at each stage, before the project can develop 
further to the next stage. At the Phase I stage, the idea 
for  the project is  first mooted and  documentation is 
brief. The comments for this phase, include comments 
on  the  feasibility  of  the  concept,  but  at  present 
ACIAR  has  limited  expertise  to  comment  in  detail 
about biotechnology projects.  At Phase  2,  more de-
tailed documentation is presented against a pro-forma, 
and comments are also sought from external referees. 
At the  third  phase (Phase 3),  documentation on the 
project is  greater with all  comments  including  those 
of in-house review, the external referees and ACIAR's 
Board of Management,  having  been addressed.  The 
last phase (Phase 4) is the signing off stage at which 
the  project  has  the  necessary  authorisation  to  com-
mence, except for the signing of the Memorandum of 
Understanding with the country concerned. 
ACIAR's options are: 
to  leave the assessment on the feasibility  and on 
biotechnology issues  to  external reviewers  at  the 
Phase 2 or 3 stage; 
to acquire, develop or contract sufficient expertise 
to  be  able  to  assess  feasibility  of concept at  the 
Phase 1 stage. 
In the  interests of efficiency  and effectiveness,  it is 
desirable to make assessments at the Phase 1 stage, so 
that  projects  which have  little likelihood of success 
are  weeded out early, before reaching Phase 2 where 
more documentation is  needed. This will  save work 
for  the project leader and for ACIAR in the long run. 
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It is  also important to  seek advice on biotechnology 
issues  such  as  biosafety  and  the  capabilities  of 
particular partner country institutes. As an alternative 
to having such expertise in-house, ACIAR could have 
a short-list of 'consultant reviewers'  paid  an  honor-
arium if necessary, where RPCs require advice at the 
Phase I stage. This represents the most cost-effective 
way  to  import the most current biotechnology skills 
when needed. 
Recommendation 3 
That ACIAR consider acquiring, developing or 
contracting sufficient expertise to assess the 
feasibility-of-concept in biotechnology projects, 
and to advise on issues such as biosafety and the 
relative capabilities of particular institutes to carry 
out biotechnology projects at the in-house review 
process. 
Commercialisation Issues 
The use  of biotechnology in  agricultural research  is 
more  likely  to  lead  to  the  development of a  novel 
product,  i.e.  new  probes,  useful  DNA  sequences, 
genetically  engineered  vaccines,  novel  germplasm 
(i.e. resistant to pests) novel biological control agents, 
than the use of conventional methods. Such research is 
likely  to  result  in  a  benefit  that  can  accrue  to  the 
private sector rather than, or in conjunction with being 
a  'public good'.  Research  using  biotechnology may 
be  subject  to  patents  and  may  require  intellectual 
property management more than traditional biological 
technologies.  This  accentuates  the  debate  about  the 
extent to which the public sector should be involved in 
funding  biotechnology,  for  example,  the  publicI 
private good dichotomy. 
It  was  seen in Chapter 4  that one of Australia's 
weaknesses  is  the  relative reluctance of the  private 
sector to  invest in research. For a variety of reasons, 
including the long lead time, uncertainty of outcome 
(high risk),  uncertainty  about the regulatory climate, 
lack  of confidence  in  public perceptions on genetic 
engineering,  the  private  sector  in  Australia  is  un-
willing to  invest in pIe-competitive research biotech-
nology.  Unless  the  overall  investment  climate, 
including government policies, changes significantly, 
there  is  a  role  for  public sector investment  in  such 
research.  However,  at  a  certain  point in the  devel-
opment of a product, after the basic research stage, the 
private sector may fmd investment attractive, particu-
larly if benefits can be accrued from research which is largely  publicly  funded.  In Australia,  as  elsewhere, 
there is  a tendency to  'privatise' public research and 
development.  Private  investment  in  agricultural  re-
search seldom occurs in the  absence of an  effective 
public research system. 
There  is  a  view  that  if investment  in biotech-
nology  is  completely  left to  market  forces  (without 
policy intervention), the private sector might invest in 
high value products,  such  as,  high yielding  animal 
species,  horticultural  crops,  (e.g.  blue  roses),  while 
cereal and food crops might become 'orphan' crops. 
As with traditional agricultural research, biotech-
nology may also lead to  a purely  'public good' out-
come,  with a benefit that cannot be appropriated by 
the private sector. As has been the case traditionally, it 
is  the  role  of ACIAR  to  continue  to  fund  such  re-
search. 
In view of these considerations,  ACIAR has the 
following options: 
continue to fund only pure 'public good' research; 
fund projects only where there is little likelihood 
of a product developing (pure basic research); 
fund projects in the pre-competitive stage, so that 
companies can pick up from where public funding 
left off and 'privatise' the research; 
fund projects in the pre-competitive stage together 
with the private sector on a fonnula basis; 
only fund work at the product development stage. 
The first option is the status quo, and ACIAR needs to 
continue  to  support  this  important  category  of 
research.  Without  public  support,  there  is  a  grave 
danger  that  this  sort  of research  will  be  neglected. 
However with biotechnology, funding only this sort of 
research may limit the attainment of program objec-
tives  by  excluding  research  leading  to  patentable 
outcomes. 
The second  option  is  not  tenable  in  a  climate 
where projects are assessed ex ante  and  ex post for 
economic benefits and is  against ACIAR's mandate, 
although it can be argued that capacity building is an 
important benefit which will  allow  the development 
of other products in the future. The second option is 
viable but not necessarily in the interests of ACIAR's 
partners because ACIAR will have little influence on 
how the IPR might be  apportioned. The result might 
be that the developing country does not get access to 
the  technology  at  a  reasonable  price.  By  the  same 
token, Australia may not benefit if a company in the 
developing country commercialises  the  product. The 
last  option  goes  against  conventional  economic 
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wisdom  on the  role  of public  investment,  and  will 
completely 'crowd out' the private sector. 
If ACIAR  were  to  fund  projects  on a  formula 
basis  together  with  industry  funding,  the  research 
would not be wasted, but would result in an economic 
benefit which can be distributed on terms acceptable to 
ACIAR and in accordance with ACIAR's mandate as 
an  international  agricultural  research  agency.  The 
participation  of  the  private  sector  ensures  further 
development and  commercialisation of the  research. 
Further, it is difficult for any public research agency to 
market products commercially off-shore, neither is a 
public  institution  best  placed  to  enter  into  joint 
ventures with multinational companies. 
In  order  that  the  maximum  economic  benefits 
accrue  to  Australia,  it  is  suggested  for  any  ACIAR 
funded  biotechnology  projects,  that  an  Australian 
research  and  development  company  able  to  market 
products overseas, be associated with the project. This 
company  will  be  given IPR  in partnership with the 
partner country, in accordance with ACIAR's present 
policy of equitable distribution of such rights. In order 
to secure the commercial interests of that company, it 
is proposed that the company fund a proportion of the 
research (i.e. dollar-for-dollar or some other fonnula). 
Recommendation 4 
If  there is potential for a marketable product to be 
developed from the research, where feasible, an 
Australian company capable of marketing the 
product overseas could be associated with the 
project from its inception, and efTorts be made to 
secure appropriate proportional (or matching) 
funding from the company. 
Intellectual Property Rights 
Research  using  biotechnology  is  more  likely  than 
conventional research to  lead to  patentable outcomes 
and it may be appropriate to  review  ACIAR's policy 
on  IPR  in  this  regard.  The  'Standard  Conditions 
Relating  to  ACIAR  Project Agreement'  contains the 
following  clause  relating  to  the  ownership of intel-
lectual property: 
The ownership  of all intellectual property rights 
protected or derived or arising solely from the perfor-
mance of the  services  be  the  subject of a separate 
agreement  entered  into  between  the  Commissioned 
Organisation  and the  Collaborating  Institution,  and 
shall  be  apportioned  on  the  basis  of the  equitable 
criteria .... unless  otherwise agreed  in  writing  by  the 
parties and ACIAR. The philosophy of equitable sharing of rights  is 
appropriate for an agency disbursing public funds to 
assist developing countries under the aid budget and 
is compatible with that of other international research 
organisations.  The  document  also  states:  ail  intel-
lectual  property  rights  ... shall  vest  in  the  Com-
missioned Organisation if  they are rights protected in 
Australia,  and  shall  vest  in  the  Collaborating 
Institution if  they are rights protected in the country of 
the Collaborating Institution. 
Developed  countries  are  at  present  either  ex-
tending patent laws (which traditionally cover indus-
trial  applications,  and  which  provide  stronger 
protection than other forms of traditional plant variety 
protection)  to  biotechnology,  or  have  laws  which 
already allow for the protection of biotechnology pro-
ducts. It is beyond the scope of this paper to  discuss 
other forms of non-legislative protection. 
On the other hand, few developing countries have 
such patent coverage, and in general,  as  users rather 
than  developers  of  the  technology,  it  is  in  their 
interests  to  have  little  or no  patent protection.  See 
Appendices 5 et seq for the intellectual property status 
of partner countries with a biotechnology capability. 
Difficulties in accruing rights protected by legislation 
arise for  a number of partner countries which do not 
have  patent  protection  for  biotechnology.  At  best, 
protection of biotechnology is  ambiguous until tested 
in  countries  including  Malaysia,  Vietnam  and  Indo-
nesia. Signatories to the Uruguay Round of GATT are 
expected  to  define  explicitly  some  form  of  legal 
protection for microorganisms and plants, and conse-
quently, developing countries are now considering the 
explicit inclusion of biotechnology in IPR legislation, 
where it may otherwise be implied or excluded. 
What this means is that there is little incentive for 
an  agency  to  come  up  with  a  patentable  product, 
which might be  freely  disseminated in a developing 
counlIy,  and  thus  undermine  any  existing  patent 
protection  in  Australia.  Under  these  circumstances, 
ACIAR's role would be to specify the terms on which 
the  partner  counlIy  has  access  to  the  technology, 
either  through  compulsory  licensing  or  other 
contractual arrangements,  which could include  strict 
instructions  to  prevent  further  dissemination  of the 
technology. It is particularly important to  ensure that 
the  developing  country  receives  access  to  the 
technology on more favourable terms than any other 
country, particularly if the germplasm which led to the 
development of the product originated in the counlIy 
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coneerned  (See  also  discussion  on biodiversity  in 
Chapter 7). 
As was  seen in the  previous section, the use of 
biotechnology  is  more likely to  lead to  a patentable 
product  than  conventional  agricultural  research.  In 
ACIAR's  project  development  procedures,  it  is 
important to seek a statement of intent relating to !PR 
from  the  commissioned organisation in the Phase 2 
pro-forma document,  in order to  have no ambiguity 
about the apportioning of IPR. It should also be noted 
that  industrial  ownership  is  more  secure  if repro-
ductive  isolation  is  genetically  engineered  into  the 
product along with the characteristic of interest. 
ACIAR has the following options: 
ignore the !PR issue in project pro-formas; 
seek  a  clear  statement  from  the  Commissioned 
Organisation from  the  outset,  and ensure access 
by the developing country on equitable terms. 
The first option may result in the  possibility of 
ACIAR's expenditure on the project being wasted due 
to  the  private  sector  subsequently  capturing  the 
benefits of the research. Thus the benefits may not be 
realised for the partner country. 
Recommendation 5 
That ACIAR's policy of the equitable allocation of 
intellectual property rights is appropriate for 
biotechnology, and that the Phase 2 proforma be 
amended to seek a statement on the allocation of 
IPR from the commissioned organisation at that 
stage of project development. ACIAR could 
examine the mechanism of compulsory licensing 
arrangements for spillover benefits to other 
developing countries which might otherwise find it 
difficult to access the product. 
The patenting of animals and genetic sequenees is 
considered to raise ethical issues, and is the subject of 
much international debate.  ACIAR needs to  adopt a 
cautionary stance with regard to  projects  where  the 
such patenting is contemplated. 
8iosafety 
The  release  of genetically  engineered  live  plants. 
animals,  or  microorganisms  (GMOs)  is  associated 
with an uncertain degree of risk that the construct may 
have  undesirable effects  on  the  environment (e.g.  a 
weed or pollutant) and in the case of crops and edible 
plant products and biopesticides, or biological control 
agents,  risk  toxicity  to  humans when consumed. Put 
into  overall  perspective,  of some  1000  releases  of transgenic plants arOlmd  the world, no actual hazard 
has  yet been  identified.  However,  appropriate  bio-
safety  assessment  of  all  genetically  manipulated 
organisms  and  field  testing  with  monitoring  is 
essential  to  allay  concerns  and  to  establish  safety. 
There is  also  a perception in some quarters that the 
developed countries could be  'dumping' unsafe pro-
ducts  on  developing  countries  unfamiliar  with  the 
technology.  The  unapproved  release  of  GMDs  in 
developing countries could well reflect adversely on 
ACIAR's international reputation. 
As  seen  in  Chapter  4,  Australia  has  a  good 
regulatory system and one of its strengths is expertise 
in the area of biosafety assessment for the release of 
genetically  manipulated  organisms.  GMAC  has  as-
sessed some 45  release proposals to date, of which 
about 33  are plant constructs and the  rest,  microor-
ganisms.  A  complete  list  of GMAC  approvals  is 
attached in Appendix 1. 
Assessment  is  generally  more  rapid  if  the 
construct  is  made  using  a  disarmed  vector  (with 
pathogenic  genes  deleted)  in  a  host  organism  for 
which there is a deal of familiarity, and if the inserted 
gene has these characteristics: 
is not derived from microorganisms able to  caUSe 
disease in humans, animals or plants; 
does not code for a toxin for vertebrates; 
does  not comprise  a replication-competent  frag-
ment of a virus or a whole viral genome, or a frag-
ment of a viral genome that can be made com-
petent by a host factor. 
The genetic constructs as described above are exempt 
from the small scale guidelines, but require a planned 
release assessment if release is being contemplated. 
The  National  Food  Authority  has  adopted  the 
DECD concept of 'substantial equivalence' for the ap-
proval  of genetically  manipulated  organisms  to  be 
marketed as  food.  The food will attract no additional 
labelling requirements in Australia if these criteria are 
met: 
no substance is  introduced into the diet at a level 
for  which there is  no prior established history of 
use; 
no substances are present which may be ethically 
offensive to defined group of consumers; 
no special processing is required compared to  its 
conventional counterpart; and 
when  prepared  for  consumption,  it  does  not 
contain  any  substances,  not normally present in 
the conventional counterpart, which are known to 
be harmful to particular individuals. 
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nutritional qualities are not diminished compared 
to a traditional counterpart. 
When a genetic manipulation is proposed in a project. 
it may be necessary for RPCs to review these criteria 
in order to ensure that the construct is likely to be safe 
and meet regulatory hurdles without much difficulty. 
Any other option may lead to delays or difficulties in 
getting approval for release in Australia at the end of 
the  project.  RPCs  may  also  use  the  services  of 
external  'Consultant  Reviewers'  to  advise  on these 
aspects. 
Recommendation 6 
ACIAR's Research Program Coordinators should 
be aware of the criteria for biosafety and food 
safety assessment at the genetic construct stage if  a 
genetically manipulated organism is contemplated 
in the proposal, 
ACIAR's partner countries  are just beginning to 
set up biosafety regulatory mechanisms, but there is 
little  experience  and  confidence  in  this  area.  See 
Appendices 5 et seq  for  details. The Philippines has 
inappropriately  stringent regulation which  is  stifling 
biotechnology  research  in  that  country.  An ISNAR 
publication (Persley et al. 1993) has suggested that all 
nations set up biosafety committees. The IARCs  are 
either setting up. or have already established in-house 
biosafety committees, as recommended by ISNAR. 
It  is  suggested  that  for  all  proposed  ACIAR 
projects  involving  the  production  and  relel.'l5e  of a 
genetically  manipulated  organism,  the  Australian 
Commissioned  Organisation  begin  dialogue  with 
GMAC at the Phase 2 stage (and certainly before the 
signing-off stage)  about  safety considerations of the 
proposal. ACIAR's responsibility is  to ensure that the 
Australian  project  leader  is  made  aware  of his/her 
responsibilities in terms of seeking GMAC advice, so 
the proforma  at  Phase  2 should  include a  question 
asking  if this  project  falls  under  the  GMAC  guide-
lines, and if so, an undertaking from the project leader 
that GMAC assessment and advice will be sought. 
As  well,  the  'Standard Conditions' document or 
Memorandum of Understanding could be amended to 
state  explicitly  that  the  responsibility  for  getting 
approval  from  appropriate  national  authorities  to 
release genetically engineered organisms, lies with the 
agency  in  the  developing  country.  Where  such 
regulatory mechanisms do not exist, advice should be 
sought from  an IARC, if there is  one located in the 
country. If  not, ACIAR should assist the agency itself to conduct a formal in-house biosafety review. Where 
possible ACIAR could try to ensure that Australian 
regulatory and assessment procedures are adhered to 
as a minimum standard. Any advice from GMAC on 
monitoring  requirements  should  be  set  out  in  the 
protocol for the field trials and the results be included 
in  the  project  reports  to  ACIAR  (Le.  the  project 
annual reports). 
The option of not undertaking  the above proce-
dures  would  leave  ACIAR  and  the  Australian 
Government vulnerable to  the claim made by some 
non-government organisations that developing count-
ries are being used as a testing ground for genetically 
modified  organisms,  so  as  to  avoid  the  stringent 
regulations prevailing in the industrialised countries. 
ACIAR, as an Australian Government agency has  a 
duty of care to ensure that regulatory systems set by 
another Government agency are not inadvertently by-
passed. 
Recommendation 7 
The project pro-forma at the Phase 2 stage o( 
project development should require explicitly, that 
the Australian project leader take responsibility 
for obtaining any necessary approvals, including 
ethical approval for animal experimentation from 
institutional ethics committees within the 
Australian commissioned organisation, and for 
any clearances for genetic manipulation work 
falling under the guidelines of the Genetic 
Manipulation Advisory Committee (GMAC). 
Recommendation 8 
If  the field trialing of a genetically manipulated 
organism (GMO) in a partner country is proposed 
in a project, ACIAR should formally advise the 
relevant Ministry in the partner country of the fact 
prior to the release of the GMO so that any 
necessary clearances can be obtained. This notifi-
cation can be undertaken with the contractual 
documentation for the project or subsequently, if 
the release was not foreseen at the Inception of the 
project. Where feasible, GMAC advice on the 
monitoring requirements of the trial should be sent 
to the Project Leader In the partner country. 
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Recommendation 9 
Where It Is clear that the partner country has no 
regulatory or advisory system for the assessment 
of the environmental release of genetically 
manipulated organisms, the advice of the in-house 
biosafety committee of the relevant International 
agricultural research centre could be sought, If 
such a centre exists in that country. If  not, ACIAR 
may need to assume the responsibility for 
commissioning such assessment in the partner 
country. 
Project Criteria 
ACIAR's project criteria are as follows: 
Approaches to ACIAR should be made formally 
through  agreed  developing  country  national  re-
search organisations, and have their endorsemenL 
ACIAR  should  respond  to  research  priorities 
established by potential partner countries with the 
'push'  coming  from  the  developing  country. 
ACIAR makes these countries aware of  Australian 
research capabilities  and  its  capacity  to  respond, 
and  indicates  whether the  proposed project falls 
within ACIAR's own priorities. 
Research  priorities  should be planned jointly so 
that there is a partnership from the beginning. The 
plans must be explicit. stating what will be done 
by both sides, and provide a timetable of proposed 
activities. 
Where possible ACIAR support should capitalise 
on existing strengths in Australia, and also in the 
developing  country,  to  ensure  that  the  commit-
ment  is  real  and  that  support  will  enhance  the 
prospects for successful research. Some assurance 
that the  activity  is  sustainable and will continue 
after ACIAR support ceases, is also SOUghL 
Research  supported  by  ACIAR  must  focus  on 
soluble problems  that  will  give  results  having  a 
wide  application  in  developing  countries,  and 
bring mutual economic and scientific benefits both 
to developing country partners and to Australia. 
These  general  criteria  are  also  relevant  for  bio-
technology projects. Any other option would minimise 
the chances for success. 7. Multilateral Policy Issues 
Biodiversity and Sustainability 
IT is likely that many of the future superior agricul-
tural products will be developed by the use of biotech-
nology.  Continued  improvement  depends  upon  the 
availability  of  new  unimproved  gerrnplasm  with 
characteristics not previously assessed, which can be 
subsequently modified for use in modem agricultural 
systems. Most sources of unimproved germplasm for 
crops of agricultural significance and their centres of 
biodiversity  lie  in  developing  countries,  and  future 
access to gerrnplasm will be governed by the terms of 
the  Biodiversity  Convention.  Developing  countries 
may seek access to  germplasm improved by biotech-
nology in return for  access to  their biodiversity. The 
Convention is thus intricately linked to biotechnology. 
Biotechnology  has  an important role  to  play  in sus-
tamability,  because  applications  can  lead  to  greater 
yields  with  current  inputs,  with  present  land  under 
cultivation,  and  thus  are  more  environmentally 
friendly.  Biotechnology  can  also  lead  to  greater 
sustainability of land and resource use (e.g. transgenic 
pest-resistant crops). 
The Convention on Biological Diversity signed by 
150  countries,  including  Australia,  at  the  United 
Nations  Conference  of  Environment  and  Devel-
opment at Rio de Janeiro in 1992, seeks to make the 
conservation  of biodiversity  and  sustainable  use of 
genetic resources  a global responsibility  for  the first 
time. This Convention, which is legally binding, came 
into  force  in  December  1993.  It was  ratified  by 
Australia  in  1993  and  by India,  China,  and  all  the 
countries  with  a  biotechnology  capability  in  the 
Southeast Asian region.  See Appendix  12  for  a full 
list of mandate countries  with current  ACIAR  pro-
jects, which have signed and ratified the Convention. 
Other conventions and  treaties  which have some 
relevance to the conservation of biological resources, 
to which Australia is a signatory, are: 
Convention on the  Conservation of Nature in the 
South  Pacific,  1976  (known  as  the  Apia  Con-
vention); 
Convention for the Protection of  Natural Resources 
and the Environment of the South Pacific, 1986; 
The World Heritage Convention; 
The  Convention  on  Wetlands  of  International 
Importance  Especially  as  a  Waterfowl  Habitat 
(RAMSAR Convention); 
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The  Convention  on  International  Trade  in 
Endangered  Species  of Wlld  Fauna  and  Flora 
(CITES); 
Agreement  on  Trade  and  Related  Aspects  of 
Intellectual  Property  Rights,  including  trade  in 
Counterfeit  Goods  (Annex  lc  of  the  GAIT 
Uruguay Round); 
The United Nations Law of the Sea Convention. 
There are further Conventions and treaties relating to 
the rights of indigenous peoples. These other instru-
ments  are not  legally  binding  and it is  beyond  the 
scope of this paper to consider Australia's obligations 
under them. 
Under the Biodiversity Convention, countries are 
given sovereignty  to  their own genetic  resources  in 
return  for  a  commitment  to  adopting  policies  on 
conservation. The Convention requires Parties to con-
sider the need for international protocols for biosafety. 
Access  to  genetic  resources  is  subject  to  informed 
consent  and  should  be on fair  and  equitable  terms. 
Indigenous people's right to consultation and compen-
sation, is also raised in the Convention. 
It can be  seen  from  Appendix  12  that  all  the 
countries which have a biotechnology capability have 
signed the Convention and are currently considering 
safeguarding access to their biodiversity so that scien-
tists  from  developed  countries  cannot  go  'bio-pro-
specting' in their forests in the future. This means that 
costs or conditions may be attached to  the access and 
use of germplasm originating from these countries in 
the future.  An important condition may be access to 
biotechnology from developed countries. Article 16.2 
states that access and transfer of  technology to devel-
oping  countries  shall be provided and/or facilitaJed 
under fair and most favourable terms. including under 
concessional  and preferential  terms  where  mutually 
agreed  .... 
Another  important  document,  which  has  been 
signed  by  107  countries,  is  the  FAO  International 
Undertaking  on  Plant  Genetic  Resources,  which 
safeguards  the principle of free  exchange of genetic 
resources  for  scientific  purposes.  The  rights  of 
farmers  to  have  access  to  the  benefits  arising  from 
improved germplasm,  is  protected in this  document. 
Genetic  resources  are  recognised  as  a  common 
heritage to  be available for use by present and future 
generations  of all  countries.  The  FAO  is  currently 
considering  amending  the  document  to  make  it 
compatible with the Biodiversity Convention. While the Undertaking is being revised, it may be 
important  for  Australia  to  adhere  to  the  voluntary 
International Code of Conduct for  Plant Germplasm 
Collecting  and  Transfer  adopted  by  the  FAO  in 
November  1993,  which  provides  guidelines  re-
questing  collectors  to  seek  permits  from  national 
governments,  and  sets  out minimum responsibilities 
for  collectors,  sponsors  and  users  of the  collected 
germplasm. Although this will add to  the paperwork, 
approval  from partner countries should be sought in 
projects where it is  envisaged that germplasm would 
be  collected.  The  option  of  not  having  formal 
permission may lead to disputes subsequently relating 
to ownership of the germplasm under the terms of the 
Convention, and of any improved germplasm arising 
from it. 
Recommendation 10 
Where it is envisaged that germplasm is to be 
collected in a project, the Memorandum of 
Understanding (MOU) for the project should 
foreshadow this, and seek approval from the 
national government under mutually acceptable 
terms, 
Australia was represented at  the  first Conference 
of the Parties (COP1) where the need for  a protocol 
was raised, and at COP2 in November 1995, Australia 
will need to have a position on whether it supports the 
establishment  of  a  protocol  on  biosafety.  For  the 
purpose of considering  these  issues,  an  interdepart-
mental committee has been established, chaired by the 
Department of Foreign  Affairs  and  Trade.  As  well, 
subsequent to  Australia signing  the Convention,  the 
Coordinating Committee on Science and Technology 
of the  Office  of the  Chief  Scientist,  established  a 
working party to  examine what action, if any, needed 
to  be  taken  domestically  to  protect  access  to 
Australia's genetic resources and to  obtain a fair  and 
equitable benefit from their exploitation. It was recog-
nised in the ensuing report that there are currently no 
mechanisms for  addressing these issues and an inter-
departmental  committee  has  been  established  to 
consider these matters. 
Australia  relies  on  imported  exotic  genetic 
resources for  its major food crops and for agriculture 
and  some  initiatives  have  been  taken  to  safeguard 
access to these, such as the establishment of a national 
network  of  genetic  resource  centres  to  conserve 
germplasm of strategic and economic importance, and 
to  link the  Australian network with that proposed by 
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the  FAO.  In contrast,  Australia  has  a  rich  store of 
endemic  forest  tree  germplasm  and  can  and  does 
benefit from export of tree seeds. 
It  has  been  argued  in  'Environment  and  Agri-
culture'  (Winrock  International  Institute  for  Agri-
cultural  Development,  1994),  that  development 
agencies need to  take a major role in the debate on 
genetic conservation and biodiversity. This argument 
is  based on the fact that development agencies have a 
duty  to  safeguard major crops relied upon by  all  of 
humanity  for  food.  The  sources  of diversity  from 
which  future  improvements  of this  germplasm  can 
arise  lie  in  developing  countries.  However,  devel-
oping  countries  have  inunediate  pressures  to  meet 
existing  food shortages and may erode this diversity 
by  alternative use of the land which supports biodi-
versity.  Development  agencies  are  in  a  position  to 
fund both ex silu and in situ conservation projects and 
thus  be  the custodians of food crop varieties needed 
for meeting the demands of increasing global popula-
tions and of future generations. 
ACIAR,  whose  mandate  is  funding  agricultural 
research, particularly needs to be involved both at the 
domestic and intemationallevels, for these reasons: 
eighty  per cent of genetic diversity  is  found  in 
developing  countries  which  are  ACIAR's 
partners; 
ACIAR activities will be directly affected by the 
existence of any protocol, and the  free  exchange 
of  germplasm  for  scientific  research  could  be 
jeopardised; 
the  international agricultural research community 
can provide the funds which developing countries 
require  for  research  associated  with  the  conser-
vation of biodiversity; 
ACIAR has expert scientific knowledge on plant 
genetic resources and their sustainable use; and 
ACIAR  has  both the  technical and  the  financial 
resources  to  meet Australia's obligation to assist 
conservation in developing countries. 
Since  biodiversity  is  a  global  responsibility,  any 
ACIAR  initiatives  should  be  coordinated  and  in-
tegrated with other international efforts, and cannot be 
successfully  undertaken  on  a  bilateral  basis.  Thus 
ACIAR needs  to  be  involved at relevant multilateral 
fora.  It is also essential for ACIAR to be represented 
on any domestic interdepartmental committees estab-
lished  under  Australia's  obligations  from  the  Con-
vention,  and for  ACIAR to  be part of the Australian 
delegation  to  any  expert  meetings  arising  from  the Convention.  ACIAR needs  to  formalise liaison with 
the  Commonwealth  Department  of Foreign  Affairs 
and Trade so that it is invited to participate in policy 
which may impact on its activities. 
Any  other  option  would  leave  ACIAR  in  a 
position of having its activities affected without being 
in a position·  to influence outcomes. These activities 
can only be successfully undertaken on a multi-lateral 
basis, and are discussed in the subsequent sections. 
Recommendation 11 
That liaison with the Commonwealth Department 
of Foreign Affairs and Trade be strengthened so 
that ACIAR Is represented on relevant Australian 
Government inter-departmental committees set up 
to consider Australia's obligations under the 
Biodiversity Convention, and on any international 
expert meetings related to the Convention. 
International Agricultural Research Centres 
The network  of International  Agricultural  Research 
Centres  (IARCs)  is  supported  by  the  Consultative 
Group  on  International  Agricultural  Research 
(CGIAR),  which  provides  funds  and  technical  and 
policy advice to the Centres. ACIAR is now (since its 
'sunset'  review)  responsible  for  Australian  funding 
for  the  IARCs,  and  is  a  donor  and  member  of the 
CGIAR.  The  CGIAR  accords  high  priority  to  the 
conservation of ex situ  plant genetic  resources,  and 
one of its  institutions.  International Board for  Plant 
Genetic Resources, is entirely dedicated to stimulating 
work on conservation, while the other centres concen-
trate on their mandate commodities. The trusteeship 
of all germplasm held by the Centres has been trans-
ferred to the FAO to be held for the use of  present and 
future  generations  for  all  countries  of  the  world 
without  cost.  Currently,  IARC  collections  do  not 
include  animals,  microorganisms, ornamental plants, 
or trees for timber. 
As seen in the preceding section, the Convention 
on Biological Diversity (CB D) requires signatories to 
undertake  in  situ  conservation  activities,  and  it is 
unlikely  that  developing  countries  will  devote 
resources to this activity when more immediate goals 
such as  food self-sufficiency are not met. The Conv-
ention  specifically  states  that  developed  countries 
'shall provide new and additional financial resources' 
(Article 20.2) to enable developing country Parties to 
meet  their  obligations  under  the  convention.  In 
allocating  its  funding  to  the  IARCs,  ACIAR  could 
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give  consideration  to  funding  specific  research 
projects  involved  with  the  in  situ  conservation  of 
genetic diversity, in addition to its funding of specific 
centres involved in ex situ germplasm conservation. 
and  thus  meet  Australia's  obligations  under  the 
Convention. 
Recommendation 12 
That in allocating runds to the International 
Agricultural Research Centres (IARCs), ACIAR 
give consideration to rundlng projects in 
developing countries involving research associated 
with the conservation or germplasm, including in 
situ conservation, so that the international research 
community may be more likely to be granted 
continued access to endemic germplasm. 
The lARes are now embracing biotechnology and 
are investigating  the  associated policy issues arising 
from  this  technology.  The international  activities  in 
biotechnology  are  summarised  in  Appendix  11.  To 
avoid duplication of effort, 10 strengthen linkages, and 
to  ensure  efficient  use  of  human  resources  and 
expertise,  it  is  important  that  any  bilateral  project 
which  is  related  to  an  existing  or  proposed  IARC 
project.  should  be  coordinated  with  the  !ARC 
program. No identical project should be  funded  from 
ACIAR bilateral funds,  and for related new  projccts, 
the  Australian  commissioned organisation  should  be 
asked to collaborate with the IARC in order to ensure 
that there is  a value-adding component to  Australian 
involvement. 
Recommendation 13 
That ACIAR be aware or the programs or  the 
IARCs and or new projects, including 
biotechnology projects, so that there is no 
duplication of research effort, but a 
complementarity is achieved to add value to the 
work ofIARCs. 
Biotechnology  depends  upon  the  availability  of 
germp\asm  resources  as  its  starting  material  and 
converts  it  into  improved  germplasm.  which  may 
attract  patent  protection.  Unfortunately  the  Con-
vention on Biological Diversity has little to say about 
access to improved germpJasm except that developing 
countries  should  have  access  'wuler fair  and  most 
favourable terms'  (Article 16.10), and in  the case of 
germplasm  subject  to  patents  'on  terms  which 
recognise and  are  consistent with  the adequate and effective  protection  of IPR'  (Article  16.2).  Present 
COIAR policy states that Centres can consider taking 
out proprietary protection of improved germplasm on 
a case-by-case basis, and each Centre is free to devise 
its own policies in this regard. 
Recently, a review of genetic resources within the 
COIAR Centres, recommended that genetic resources 
in  the  centres  be  integrated  and  funded  as  single 
program so that policies can be developed and coordi-
nated for the Centres as a whole. 
ISAAA 
The International Service for the Acquisition of Agri-
biotechnology  Applications  (ISAAA),  founded  in 
1991  is  a  non-profit organisation  whose  role  is  to 
transfer and apply proprietary biotechnology products 
to  developing  countries. It has  successfully  demon-
strated the feasibility of transferring such technology, 
by means of a model project involving the donation 
from Monsanto of a potato construct with the Alpha 
viral coat protein genes, to a Mexican research insti-
tution. 
ACIAR's role and relationship to  other multina-
tional  bodies  with  regard  to  training  and  capacity 
building is discussed in Chapter 8. 
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Role of Other Donors and Multilateral Agencies 
THE  role  of other  international  institutions  with  a 
biotechnology  training  mandate  in  the  Asian  and 
Southeast Asian region, is summarised as follows: 
International  Service  for  National  Agricultural 
Research (ISNAR), has an Intermediary Biotech-
nology Service which runs  seminars,  workshops 
and  disseminates  publications  on  issues  in  bio-
technology. 
International Centre for  Genetic Engineering and 
Biotechnology  (lCGEB)  located  at  Delhi  and 
Trieste  offer  long  term  training  fellowships  to 
undertake research at the two  locations and short 
term  training  courses  on  specific  scientific 
research topics such as biosafety assessment. 
International Service for the Acquisition of Agri-
biotechnology Applications (IS AAA) has  funded 
regional workshops on biosafety. 
Biotechnology  Advisory Council  (BAC),  a non-
profit  private  organisation,  offers  services  in-
cluding assessment of safety of particular projects 
and has held biosafety  workshops  in  developing 
countries including Africa. 
The IARCs can also play a training role for scien-
tists in the country in which they are located, and 
Australian core funding to IARCs could include a 
training quantum. 
A  summary  of  the  activities  undertaken  by  these 
bodies is contained in Appendix 11. In general (except 
fOl  the  ICGEB), these organisations offer advice on 
policy  and  management  issues  in  biotechnology. 
These  courses  take  researchers  out  of  their  own 
research environments for training elsewhere, often in 
another  developing  country.  ACIAR  should  not 
duplicate the work of these agencies but try to com-
plement their  activities.  It would not be appropriate 
for ACIAR to hold theoretical seminars and workhops 
in aspects  of biotechnology in developing  countries 
but ACIAR could consider funding Australian experts 
to  resource these seminars, or ear-mark funds  to  the 
Crawford  Fund  (see  below)  for  this  purpose.  This 
would be a cost-effective way to  meet training needs 
for  specific  objectives  such  as  management  of 
projects,  biosafety  or  other  biotechnology  policy 
issues. 
ACIAR's options are: 
to  conduct  policy  advisory  courses  in  biotech-
nology; 
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to  capitalise  on  such  courses  already  being 
conducted by other donors. 
The first option would duplicate courses already being 
conducted in ACIAR's geographic mandate regions. It 
is  more cost-effective to  add value to  these courses. 
Although  funding  should  be  sought  in  the  first 
instance  from  the  donor  concerned,  ACIAR  could 
consider funding resource people in situations where 
there is  a clear advantage for  ACIAR  to do so,  for 
example, when the particular courses concerned meet 
ACIAR's training objectives. 
Recommendation 14 
That ACIAR consider funding Australian experts 
as resource persons in biotechnology training 
programs and courses organised by other donors 
in the region when they meet ACIAR's training 
objectives. 
Building Research Capacity 
It was seen in Chapter 5 that one of the input costs of 
biotechnology  for  developing  countries  is  the  high 
human  capital,  since  expertise  and  knowledge  is 
required for the application of biotechnologies. It was 
also  seen  that  biotechnology  is  likely  to  be  most 
effective  when  integrated  into  existing  research  in 
countries which  already have a research capacity in 
the commodities of interest. 
Developing  countries  are  already  beginning  to 
incorporate  genetic  and  molecular  biological  tech-
niques into their on-going research programs. In order 
to  be  able  to  build  on  existing  research  in  com-
modities of interest to our partner countries, which are 
either already using biotechnology or are intending to 
use biotechnology in the near future, and for Australia 
to  capitalise  on  the  research  strengths  in  particular 
commodities of developing  countries,  it is  important 
to train partner country scientists in their own research 
environments. 
One of Australia's strengths is in the provision of 
molecular tools and skills in biotechnology. The most 
effective  way  of  building  research  capacity  is  for 
Australian  scientists  with  relevant  expertise  to 
conduct  in-house  short  courses,  seminars  and 
workshops  in  the  institutes  of  the  partner  country. 
Although  ICGEB  runs  short  technical  courses,  all 
these  courses  take  individuals  out of their  research 
environments  and  train  them  at  centres  where  the 
tools and skills that they acquire might not be relevant 
to their own agricultural problems. In-house training  relates  biotechnology  skills  to 
relevant  problems  and  enables  a  larger  number  of 
people  to  be trained  in one institute  resulting  in  a 
genuine  increase in research  capacity.  This leads  to 
synergy and to greater use and subsequent long-term 
retention  of skills.  What  might  be  forgotten  by  a 
single individual might be remembered by a colleague 
in  the  same  laboratory.  As  well  the  key  laboratory 
personnel,  laboratory  technicians,  who  would  not 
normally  be  chosen  to  attend  an  overseas  training 
program  will  benefit  from  in  situ  courses.  Such 
courses could also  include biosafety  assessment and 
advice on patenting. 
The institutes where the courses are held need to 
be carefully selected to  be  able to  support on-going 
biotechnology  activities  and  to  be  able  to  act  as 
regional centres  for  specialised commodity research. 
These  centres  could  attract  researchers  from  other 
developing  countries  to  upgrade  skills  in  particular 
commodity research. The commodity research centres 
in Malaysia are particularly suitable for further devel-
opment as regional centres of excellence, and expen-
diture on Malaysia could be justified if such courses 
include participants from neighbouring countries, thus 
ensuring spillover benefits. 
ACIAR has the following options: 
conduct  in  situ  short  biotechnology  technical 
courses in developing countries; 
conduct short courses in Australia; 
conduct only project related training. 
ACIAR  is  already  undertaking  the  second  and 
third options. It was seen in the preceding paragraphs 
that  the  most  effective  way  of building  long  term 
research  capacity  is  by  conducting  courses  in  the 
partner country. in existing research institutions. 
Recommendation 15 
In fulfilling its capacity-building mandate, ACIAR 
give consideration to funding short in situ courses 
in selected institutions in partner countries which 
can serve as regional centres of excellence, in order 
to develop and integrate biotechnology capability 
into the existing research strengths of institutions 
in partner countries. Such courses should include 
the capability to assess the safety of work with 
genetically manipulated organisms. 
Training (also see preceding section) 
ACIAR already has a long term training scheme-the 
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John  Allwright  Fellowship  Scheme,  which  enables 
about 10 project scientists from developing countries 
each  year  to  undertake  postgraduate  studies  in 
Australian  universities.  Most  of these  postgraduate 
programs  involve  training  in  biotechnology.  Long 
term training will not be further considered here. 
The Crawford Fund for International Agricultural 
Research established by  the  Australian  Academy  of 
Technological  Sciences  and  Engineering.  It makes 
more widely known the economic and social benefits 
that  accrue  from  international  agricultural  research 
and  development. It also  encourages greater partici-
pation  in  this  research  by  Australian  companies. 
governments.  agencies  and  scientific  organisations. 
and runs a training scheme to provide short periods of 
hands-on, practical training for agricultural scientists 
from developing countries. 
The Biotechnology Masterclasses in plant molecular 
biology  are  excellent value  for  money.  ACIAR  has 
provided funds  for the Crawford Fund Masterc1asses 
of $100,000 per annum for  5 years. It is  suggested 
that the Fund extend and develop the plant molecular 
biology classes so that they can run for a longer time 
to  enable  the  inclusion  of  a  plant  transformation 
experiment  The  skills  gained  in  this  course  are 
generic and can be applied to other plants. If  specialist 
courses are planned, further funding for these courses 
could be sought for the relevant industry sector by the 
Crawford  Fund. It may  also be desirable for  partici-
pants  of  courses  conducted  in  Australia  to  meet 
possible collaborators  in  Australian research  institu-
tions  and  to  establish  linkages  with  counterpart 
agencies. Such courses could also be conducted in situ 
in  partner  country  laboratories  in  order  to  build 
capacity. 
Other  Australian  based  courses  which  may  be 
recommended  to  scientists  in  partner  countries 
include: 
'Tropical  Plant  Tissue  Culture  and  Transform-
ation'  course  at  the  Department of Agriculture, 
University of Queensland; 
'Genetic  Engineering  for  Decision-Makers' 
workshop at the CRC for  Plant Science,  CSIRO 
Division of Plant Industry. 
ASEAN-Australia Economic Cooperation 
Program 
Under  the  ASEAN-Australia Economic Cooperation 
Program (AAECP) Australia provided funding (AUD 
$6.04 million) for  a joint ASEAN/Australian project on  biotechnology,  which  began  in  1989  and  was 
completed in June 1994. The objectives of the project 
include the strengthening of biotechnology capability 
in ASEAN countries. 
28 Bibliography 
ACIAR.  1994.  Standard  Conditions  Relating  to 
ACIAR Project Agreement. 
ACIAR Annual Report 1993-94. Canberra, Australia. 
Barton,  I.H.  and  Siebeck,  W.E.  1992.  Intellectual 
property  issues  for  the  international  agricultural 
research  centres.  Issues  in  Agriculture  4,  Con-
sultative  group  on  International  Agricultural 
Research. CGIAR Secretariat. 
Brenner, C. and Komen, I. 1994. International initia-
tives  in  biotechnology  for  developing  country 
agriculture.  OECD  Development  Centre,  Tech-
nical Papers No. lOO, OECD, Paris. 
Buttel.  EH.  1990.  Sociological  impact.  In:  Persley, 
G.!. ed. Agricultural Biotechnology: Opportunities 
for International Development, CAB International. 
Champ, B.R., Highley, E.  and Johnson. G.I.  1993. ed. 
Postharvest  handling  of  tropical  fruits.  ACIAR 
Proceedings No. 50. AClAR, Canberra. ACT. 
Consultative  Group  on  International  Agricultural 
Research.  1994. Stripe study of genetic resources 
in  the  CGIAR.  Teclmical  Advisory  Committce 
Secretariat, FAO. Rome. 
Coordinating Committee on Seience and Technology. 
1994. Access to Australia's Biological Resources. 
Office of the  Chief Scientist,  Department of the 
Prime Minister and Cabinet. 
Fielder,  D.R.,  Spradbrow,  P.B.  and  Dart,  PJ.  1990. 
Aquaculture.  In:  Persley,  G.J.  ed.  Agricultural 
Biotechnology:  Opportunities  for  International 
Development, CAB International. 
Genetic  Manipulation  Advisory  Committee.  1993. 
Guidelines for the Planned Release of Genetically 
Manipulated Organisms. 
Genetic  Manipulation  Advisory  Committee.  1993. 
Guidelines for Small Scale Genetic ManipUlation 
Work. 
Guerrero. R.D. 1991. An overview of the applications 
of  biotechnology  in  aquaculture  for  Asia.  In: 
Getubig, I.P., Chopra, V.L. and Swaminathan. M.S. 
ed.  Biotechnology  for  Asian  Agriculture:  Public 
Policy  Implications.  Asian  and  Pacific  Deve-
lopment Centre. 
Haines,  R.  1994.  Biotechnology  in  forest  tree 
improvement. FAO Forestry Paper, FAO. Rome. 
House  of  Representatives  Committee  on  Industry, 
Science  and  Technology.  1992.  Genetic  Mani-
pulation: the Threat or the Glory. AGPS. 
29 
Hunter,  AG.  1991.  Biotechnology  in  livestock  in 
developing  countries.  Centre  for  Tropical Veter-
inary Medicine, University of Edinburgh. Ritchie 
of Edinburgh Ltd 
International Institute of Tropical  Agriculture.  1993. 
Sustainable  Food  Production  in  Sub-Saharan 
Africa,  2,  Constraints  and  Opportunities.  IITA, 
Ibadan. Nigeria. 
Komen. J. and Persley, G. 1993. Agricultural biotech-
nology  in developing countries---a cross-country 
review.  Research  Report  No.  2,  Intermediary 
Biotechnology Service. ISNAR. 
Krattiger, A.F.  and Rosemarin A. 1994. ed. Biosafety 
for  Sustainable  Agriculture:  Sharing  Biotech-
nology  Regulatory  Experiences  of the  Western 
Hemisphere.  Sto<-kholm  Environment  Institute, 
International Service for the Acquisition of Agri-
Biotech Applications. 
Kraltiger AE et al.  1994. ed. Widening Perspectives 
on Biodiversity.  IUCN-the World  Conservation 
Union, Gland, Switzerland and International Acad-
emy of the Environment, Geneva, Switzerland. 
McSweeney  and  Associates.  1993.  Report  on 
Commercialisation of BiotechnOlogy in Malaysia. 
Ministry  of  Science.  Technology  and  the 
Environment, Malaysia. 
OECD.  1995.  Safety  Considerations  for  Biotech-
nology:  Scale-up  of Microorganisms  as  Biofer-
tilizers, OECD, Paris. 
OTA  1989.  New  Developments  in  Biotechnology: 
Patenting Life. Special Report, OTA-BA-370. US 
Government Printing Office, Washington DC. 
Pers!ey,  GJ.  1990.  ed.  Agricultural  Biotechnology: 
Opportunities  for  International  Development. 
CAB International. Walling ford. UK. 
Persley,  G.J.  1990.  Beyond  Mendel's  Garden: 
Biotechnology  in  the  Service  of  World  Agri-
culture. CAB International. Wallingford. UK. 
Persley,  G  J,  Giddings.  L  V  and  Iuma,  C.  1993. 
Biosafety: The safe  application of biotechnology 
in  agriculture and the environment. Intermediary 
Biotechnology Service, ISNAR. 
Proceedings  of the  4th  Pacific  Rim  Biotechnology 
Conference, Melbourne. 6-9 February. 
Sasson.  A.  1993.  Biotechnologies  in  Developing 
Countries:  Present  and  Future--Regional  and 
National Survey. UNESCO. Paris. 
Tribe.  D.E.  1991.  Doing Well  by Doing Good. The 
Crawford  Fund  for  International  Agricultural 
Research and Pluto Press. Tribe, D.E: 1994. Feeding and Greening the World-
The Role of International  Agricultural Research. 
The Crawford Fund for International Agricultural 
Research, CAB International. 
van Wijk 1.,  Cohen,  1.1.  and  Komen, 1.  1993.  Intel-
lectual  property  rights  for  agricultural  biotech-
nology. ISNAR, Research Report 3, Intermediary 
Biotechnology Service. 
Winrock  International  Institute  for  Agricultural 
Development. 1994. Environment and agriculture: 
rethinking  development  issues  for  the  21st 
Century.  Proceedings of a symposium in honour 
of  R  D  Havener  held  on  May  5-6,  1993  at 
Winrock International, Morrilton, Arkansas. 
30 
Xiong, 1.  and Lin,  S.  1994. ed.  Genetic Engineering 
and  Crop  Improvelllent.  Huazhong  Agricultural 
University, International Foundation for Science. 
Yuthavong.  Y.  and  Gibbons,  G.C.  1994.  Biotech-
nology  for  development:  principles  and  practice 
relevant  to  developing  countries.  ASEAN  Sub-
committee  on  Biotechnology,  National  Science 
and  Technology Development Agency, Bangkok, 
Thailand. Appendix 1 
List of GMAC Planned Release Proposals 
Assessed: 
PR-I:  Field  Ilial  of a  live  Salmonella  vaccine  to 
prevent deaths during live sheep export. 
PR-2  To test a recombinant Rhizobium  strain with a 
marker  gene  in  a  controlled  field  release 
experiment 
PR-3:  Inoculation of cattle with a thymidine kinase 
negative,  deletion  mutant,  infectious  bovine 
rhino tracheitis vaccine virus. 
PR-4:  Proposal did not proceed. 
PR-5:  National  clearance  and  registration of Agro-
bacterium radiobacter  K1026  for  control of 
crown gall disease. 
PR-6:  Commercial evaluation of melibiose utilising 
baker's yeast. 
PR-7:  Proposal considered as a Large Scale Proposal 
PR-8:  Field release of a live genetically engineered 
strain of  Pseudomona.s  for  the  purpose of 
testing a microbial tracking system. 
PR-9:  Controlled  field  release  experiment  of  a 
Rhizobium  strain  containing  a  sum  plasmid 
marked with the transposon TN5. 
PR-tO:  Proposal  under  assessment  by  the  NHMRC 
Gene Therapy Committee. 
PR-ll  Proposal exempt from GMAC Guidelines. 
PR-12  Synthetic resistance  genes  to  potato  leafroll 
virus 1991. 
PR-13  Proposal still under assessment 
PR-14  Field  evaluation  of canola  protoplast  fusion 
breeding lines. 
PR-IS: Planned release of genetically modified tom-
atoes in Australia - 1992 
PR-16:  Synthetic  resistance  genes  to  potato  leafroll 
virus 1993. 
Extension to PR-16:  Proposal for the planned release 
of  four  lines  of  genetically  engineered 
potatoes for seed tuber production. 
PR-17: Bt cotton seed increase 1993 
PR-18: Field trial of transgenic potato 
PR-19:  Planned  release  of transgenic  carnation  for 
trialing  under  commercial  glasshouse  pro-
duction conditions. 
PR-20:  Genetic engineering of cotton for resistance to 
insect pests. 
PR-21: Proposal did not proceed. 
PR-22:  Use  of  Aro  Salmonella  typhimurium  as  a 
vaccine in poUltry. 
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PR-23:  Evaluation of transgenic sugarcane plants. 
PR-24: Contained field growth of grafted apple stock 
transformed for kanamycin resistance. 
PR-25: Glasshouse  maling  of  transgenic  chrysan-
themum under non-PHI conditions. 
PR-26: Planned release of genetically modified tom-
atoes in Australia. 1993-1994. 
PR-27:  Non-chemical  control  of  bacterial  wilt 
(Pseudomonas  so/ana.cearum)  in  North 
Queens  land. 
PR-28: Planned  release  proposal  for  Ilialing  trans-
genic  carnation  with modified flower colour 
under non-contained glasshouse conditions. 
Extension to PR28/29: Proposal for extension of PR-
28 and PR-29 to an igloo trialing area. 
PR-29: Proposal  for  planned  release  of transgenic 
carnation  (ACC  synthetase,  ACC  oxidase, 
chlorsulfuron  resistance)  modified  for  en-
hanced cut flower vase life. 
PR-30:  Planned  release  of sense  suppressed,  petal 
colour  modified,  transgenic  hybrid  tea  rose 
containing  kanamycin  resistance  gene,  re-
porter gene and chalcone synthetase gene. 
PR-31:  Seed increase of Bt transgenic cotton plants, 
1994. 
PR-32: Seed  increase  and  efficacy  s('"Teening  of 
Roundup  tolerant  (RT)  transgenic  cotton 
plants. 
PR-33. Efficacy  evaluation and  agronomic  selection 
ofBt transgenic cotton plants 1994/9S. 
PR-34: Bt replicated yield and fibre  tests  and Bt vs. 
non-Bt yield test 1994/95. 
PR-35: Planned  release  of transgenic  rose  (Rosa  X 
hybrida)  containing  kanamycin  or  chlorsul-
furon  resistance  gene  and  'blue'  gene 
(flavonoid 3'5' hydroxylase). 
PR-36: Planned  release  of  transgenic  cotton 
expressing  the  CryIA(c)  or  CryIIA  delta-
endotoxins from Bacillus thuringiensis. 
PR-39: Multiple  site  evaluation  of  virus  resistant 
potatoes. 
PR-40: Release of herbicide resistant lupins (Lupinus 
angustifolius). 
PR-41:  Small  scale  planned  release  of  modified 
bovine  herpesvirus  1  for  intranasal  vacci-
nation of cattle. 
PR-42: Field evaluation of low browning potatoes. 
PR-43: Use of transgenic plants  to  monitor  the fre-
quency of Bt resistance in field populations of 
Helicoverpa armigera. 
----_._------------PR-44:  Win~er  seed  increase  of  Iransgenic  cotton 
expressing the CryIA(c) delta-endotoxin from 
Bacillus lhuringiensis. 
PR-45: Genetic  manipulation  of rumen  bacteria  for 
detoxification of the plant poison fluoracetate. 
Please  note  that  GMAC  advised  that  this 
proposal not proceed. 
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Completed ACIAR Biotechnology Projects 
PN 8367  Research and development of foot-and-













Plant  bioteclrnology  for  wheat 
gerrnplasm improvement 
The establishment of improved methods 
for  the  diagnosis  and  control  of 
livestock  diseases  in  Southeast  Asia 
using  enzyme-linked  immunosorbent 
assay (EUSA) 
Improved  immunological  methods  for 
the control of Brucellosis in ruminants 
Biology of Azolla-Aanabaena 
Improvement of the  efficiency of urea 
fertilisation of rice 
Development of an  improved haemor-
rhagic septicaemia vaccine 
Bioteclrnology of Barley Yellow Dwarf 
virus resistance in wheat 
Diagnosis  and  control  of  foot-and-
mouth disease in Thailand 
The establishment of improved methods 
for  the  diagnosis  and  control  of 
livestock  diseases  in  Southeast  Asia 
using  enzyme-linked  immunosorbent 
assay (ELISA), Phase 2 
New  approaches  to  the  control  of 
bacterial wilt 
Improved  diagnosis  and  control  of 
peanUl stripe virus 
PN 9221  Nucleotide  sequence  determination  of 
cadang-cadang-like  viroids  in  the 
Pacific 
Small Project Increased plant production through the 
treatment  of seeds  and  seedlings  with 
microorganisms 
33 Appendix 3 
Current ACIAR Biotechnology Projects 
PN 9049  Evaluation of antigens  for  vaccination 












Fowl cholera vaccines for Asia 
Management of footrot  in  small rumi-
nants in Nepal 
Improved methods for the diagnosis and 
control of bovine Babesiosis and Ana-
plasmosis in Zimbabwe and Australia 
Improved methods for the diagnosis and 
prevention  of  Coryza  in  China  and 
Australia 
Improved  methods  in  diagnosis,  epi-
demiology,  economic  and  information 
management in Australia and Thailand 
Studies in the epidemiology and control 
of bluetongue in China 
Integrated  control  of  citrus  pests  in 
China 
Application of plant tissue culture tech-
niques to the propagation and breeding 
of tea in Indonesia 
Control  of  papaya  ringspot  virus  in 
Thailand 
Detection  and  strain  differentiation  of 
plant  pathogenic  mycoplasma-like  or-
ganisms in the Australia/Pacific region 
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List of Cooperative Research Centres Relevant to 
ACIAR's Programs 
Dr H Comell, Director 
CRC for Molecular Engineering & Technology: 
Sensing and Diagnostic Technologies 
CSIRO Division of Food Science and Technology 
39~51 (Gate 1) Delhi Rd 
North Ryde  NSW 2113 
Phone: (02) 887 8495 
Pager:  (02) 963 0637 
Fax: (02) 887 3107 
Professor B E S Gunning, Co~Director 
CRC for Plant Science 
C/RSBS 
Australian National University 
Canberra  ACT  0200 
Phone; (06) 249 2330 
Fax: (06) 247 5896 
Dr G A Norton, Director 
CRC for Tropical Pest Management 
Gehrmann Laboratories 
University of Queensland 
Brisbane  QLD 4072 
Phone: (07) 365 1851 
Fax: (07) 365 1855 
Professor J B Reid, Director 
CRC for Temperate Hardwood Forestry 
University of Tasmania 
College Road 
Sandy Bay TAS  7005 
Phone: (002) 202 604 
Fax: (002) 202 698 
Dr J Hamblin, Director  . 
CRC for Legumes in Mediterranean Agriculture 
University of Western Australia 
Nedlands  WA  6009 
Phone: (09) 380 2505 
Fax: (09) 380 1140 
Professor JAG Irwin, Director 
CRC for Tropical Plant Pathology 
Level 5, John Hines Building 
University of Queensland  QLD 4072 
Phone: (07) 365 2790 
Fax: (07) 365 4771 
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Dr G Gartside, Director 
CRC for Hardwood Fibre and Paper Science 
lan Wark Laboratories 
CSIRO 
Bayview Avenue 
Clayton  VIC  3168 
Phone: (03) 5422244 
Fax: (03) 542 2223 
Dr James Hardie. Director 
CRC for Viticulture 
651 Portrush Road 
Glen Osmond  SA  5064 
Phone: (08) 3039405 
Fax:  (08) 33 9449 
Dr L R Piper, Director 
CRC for Premium Quality Wool 
CRC Headquarters 
McClymont Building 
University of New England 
Annidale  NSW 2351 
Phone: (067) 73 3609 
Fax: (067) 73 3611 
Dr B Blindon, Director 
CRC for the Cattle and Beef Industry (Meat Quality) 
CRC Headquarters 
McClymont Building 
University of New England 
Annidale NSW  2351 
Phone: (067) 733501 
Fax: (067) 73 3500 
Dr Peter Montague, Director 
CRC for Aquacullure 
University of  Technology 
Box 123 PO 
Broadway  NSW  2007 
Phone: (02) 330 1490 
Fax:  (02) 3301491 
Dr G A Constable 
CRC for Sustainable Cotton Production 
CSIRO Cotton Research Unit 
WeeWaaRoad 
Narrabri  NSW 2390 
Phone: (067) 93  1105 
Fax:  (067) 93 1186 Professor N W Dunn, Director 
CRC for Food Industry Innovation 
Department of Biotechnology 
University of  NSW 
Gate 9, High Street 
Randwick  NSW 2031 
Phone:  (02) 385 2057 
Fax:  (02) 385 1015 
Dr Ann Hamblin, Director 
CRC for Soil and Land Management 
CSIRO Division of Soils 
Hartley Grove 
URRBRAE  SA  5064 
Phone: (08) 303 8670 
Fax:  (08) 303 8699 
Dr H Tyndale-Biscoe, Director 
CRC for Biological Control of Vertebrate Pest 
Populations 
CSIRO Division of Wildlife and Ecology 
Bellenden Street 
Gungahlin  ACT  2601 
Phone:  (06) 242 1728 
Fax:  (06) 242 9242 
Professor C Crossland, Director 
CRC Reef Research Centre 
Kevin Stark Research Building 
James Cook University 
Post Office 
Townsville  QLD 4811 
Phone:  (077) 81 4976 
Fax:  (077) 814099 
Professor P Cullen, Director 
CRC for Freshwater Ecology 
Water Research Centre 
University of Canberra 
Kirinari Street 
Bruce  ACT  2616 
Phone:  (06) 201 5167 
Fax:  (06) 201 5038 
Professor J Kikkawa 
CRC for Tropical Rainforest Ecology and 
Management 
55-65 Greenslopes Street 
Edge Hill 
Cairns  QLD 4870 
Phone:  (070) 531661 
Fax:  (070) 534 945 
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Professor MichaeI Good, Director 
CRC for Vaccine Technology 
Queensland Institute of Medical Research 
The Bancroft Centre 
300 Herston Road 
Brisbane QLD 4029 
Phone:  (07) 362 0400 
Fax:  (07) 362 0104 
A/Professor Charles Webb, Dean of Science 
CRC for Sustainable Development of  Tropical 
Savaruias 
Northern Territory University 
Darwin  NT  0909 
Phone:  (089) 466550 
Fax:  (089) 466217 
Mr Andrew Crowe, Manager (Acting) 
CRC for Diagnostic Technology 
Office of Research 
Queensland University of Technology 
GPO Box 2435 
Brisbane QLD 4000 
Phone: (07) 864 2197 
Fax:  (07) 864 1304 
Dr Robert Lawn 
CRC for Sustainable Sugar Production 
James Cook University 
Department of Botany and Tropical Agriculture 
Douglas Campus 
Townsville  QLD 4811 
Phone:  (077) 815763 
Fax:  (077) 25 1570 
Dr Jim Cullen, Assistant Chief 
eRC for Weed Management Systems 
CSIRO, Division of Entomology 
GPO Box 1700 
Canberra ACT  2601 
Phone:  (06) 246 4134 
Fax:  (06) 246 4133 
Professor David Mainwaring 




Applied Science Building 
Serpen's Lane and Burwood Road 
Hawthorn  VIC  3122 
Phone: (03) 819 8576 
Fax: (03) 819 0834 Professor John Lovett 
CRC for Quality Wheat Products and Processes 
Acting Executive Director 
ORDC 
NFFHouse 
14-16 Brisbane  Ave 
Barton  ACf 2600 
Phone:  (06) 272 5525 
Fax  (06) 271 6430 
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CHINA 
1. Pkase list the main  facilities, research centres and 
institutions engaged in agricultural biotechnology 
research. 
1.  Institute of  Botany Chinese Academy of Sciences 
(CAS) 
2.  Institute of  Microbiology (CAS), Beijing 
3.  Shanghai Institute of  Biochemistry 
4.  National Laboratory  of Protein Engineering  and 
Plant Genetic Engineering of the University 
of Beijing (Beida) 
5.  Laboratory  of  Plant  Cell  Engineering  of  the 
Beijing Academy of  Agricultural Science 
6.  Crop  Germplasm  Resources  of  the  Chinese 
Academy of Agricultural Sciences (CAAS) 
Beijing 
2. What biotechnology research activities are 
conducted in these centres and  facilities? (the 
numbers in the margin refer to the institution in 
question 1) 
1.  BT maize 
potato with maize storage proteins 
alfalfa with sulphur-rich protein 
2.  caterpillar-resistant tomato 
3.  disease-resistant cereals 
improving amino acid content of chickpea 
4.  transgenic tobacco with capsid protein of tobacco 
mosaic virus 
5.  new virus-resistant strawberries 
wheat. rice and maize varieties 
disease-resistant tomato 
6.  BT preparations 
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3. What national priorities for biotechnology research 
have been identified or articulated by the 
government? 
The China  National  Centre  for  Biotechnology  De-
velopment  of the  National  Commission of Science 
and Technology coordinates all biotechnology activ-
ities,  is  funding the rice genome project, and is  sup-
porting plant and agricultural biotechnologies in more 
than 120 laboratories. 
4. What national programs in biotechnology have 
been set up and how much funding has been allocated 
for the program? 
Sce main text. 
5. Does the country have any biosafety regulations, 
protocols or guidelines for biotechnology. If  so, what 
form does this take (e.g. expert committee, 
consultants, government review, permits}. If  not, is the 
country presently drafting any guidelines or 
regulations? 
No  national  regulatory  oversight  or  committee  for 
biosafety exists in China. 
6. Does the country have any intellectual property 
righls for biotechnology. If  so, what form does this 
take (e.g. patents, plant variety righls). 
China  became  a  member  of the  World  Intellectual 
Property Organisation (WIPO) in 1980. It has patent 
legislation which excludes living plants  and animals 
but not  specifically  microorganisms.  It  covers  pro-
cessses used to produce new varieties. 
7. Is the Country a signatory to the Convention on 
Biodiversity? If  so, does the country have, or is it 
planning to draft.protocolsfor biodiversity? 
China has  signed and ratified  the Biodiversity Con-
vention. Appendix 6 
INDONESIA 
1. Please list the main  facilities, research centres and 
institutions engaged in agricultural biotechnnlogy 
research. 
1.  Centre  for 
Industrial 
(BPPT); 
the  Assessment  and  Application  of 
and  Agricultural  Biotechnology 
2.  Institute for Research and Development of Agro-
based Industry (lRDABI), Ministry of Industry; 
3.  Laboratory of Plant Biotechnology of  CRIFC; 
4.  Nutrition Research and Development Centre; 
5.  Research  and  Development Centre  for  Biotech-
nology, Indonesian Institute of Sciences (LIPI); 
6.  Research Institute for Animal Production; 
7.  Research Institute for Veterinary Scienee; 
8.  Indonesian Biotechnology Research Institute for 
Estate Crops; 
9.  Inter University Centre (lUC) on Biotechnology, 
Institut Teknologi Bandung; 
10. Department of Chemical Engineering, Faculty of 
Engineering, University of Diponegoro; 
11.  Faculty  of  Animal  Scienee,  Diponegoro  Uni· 
versity; 
12. Laboratory  of  Biotechnology,  Department  of 
Biology, Faculty of Science and Mathematics, Di· 
ponegoro University; 
13. Faculty of AgriCUlture, Sebelas Maret University; 
14. Faculty of Biology, Jendral Soedirman University; 
15. Faculty of Agriculture, Gajah Mada University; 
16. Faculty of Biology, Gajah Mada University; 
17.  Food  and  Nutrition  Development  and  Research 
Centre (FANDARC); 
18. Inter University Centre for Biotechnology, (lUC-
Biotechnology), Gajah Mada University; 
19. Jogjakarta Plantation Institute; 
20. Faculty  of  Animal  Husbandry.  Brawijaya  Uni-
versity; 
21.  Research Institute  for Tobacco  and  Fibre Crops 
(RITFC); 
22. Indonesian Sugar Research Institute; 
2. What biotechnology research activities are 
conducted in these centres andfadlilies? (the 
numbers in the margin refer to the institution in 
question 1) 
1.  Assessment and application of antibiotic process 
production; 
39 
Assessment  and  application  of  plant  seedling 
production; 
Assessment  and  application of vitamin.  enzyme 
and amino acid production; 
Production of  horticultural plants; 
Production of  vitamin B-12 (Laboratory scale); 
Consultation on antibiotic production; 
Consultation  on  tissue  culture  for  horticultural 
plants seedling production; 
Consultation on vitamin and enzyme production; 
Assessment of utilisation of local raw material for 
antibiotic production; 
Assessment  of tissue  culture  for  oil  palm  and 
somatic  and  embryo  genesis  of  Shorea  spp. 
production; 
Assessment  of  superior  fish  production  and 
superior livestock production; 
Production of horticultural plants; 
Consultation  on  somatic  embryo  genesis  of 
Shoreaspp; 
Consultation  on  superior  fish  production  and 
superior livestock production; 
Secondary  metabolites  production  of  Solanum 
plants; 
Production of erythromycin,  streptomycin, peni-
cillin and vitamin B-12; 
Consultation on antibiotic and vitamin production. 
2.  Fermentation of soybean curd  (tabu)  whey  into 
microbial cellulosic material, nata de soy; 
Quality testing of foods,  food products and other 
agro-industrial products; 
R&D  on  product  development  and  quality 
improvement for the food industries; 
Technical/consulting  services  to  the  agro-based 
industries,  especially  food,  on problem  solving. 
technoeconomics, QMS. 
3.  Analysis of RFLP of rice and bacterial leaf blight; 
Molecular technique for plant diseases and pests 
control; 
Cell  and  tissue  culture  for  rice  and  soybean 
improvement; 
VAM  symbiosis  for  increasing  P  fertiliser 
efficiency and crop yields; 
Nitrogen fixation in legumes and eereals; 
Bioconversion of plant residues  by Trichoderma 
and Cytophaga. 
4.  Nutrition and health benefits of  tempe. 
5.  Fermentation and enzyme technology; 
Plant biotechnology; 
Animal biotechnology; Production of Arnyloglucosidase; 
Production of single cell protein (microbial  and 
microalgal biomass for feed); 
Production of cattle embryos; 
Production of plantlets/seedlings of tropical fruits 
(banana.  citrus).  horticultural  species  (ginger). 
bamboo. forest tree species (Acacia and Albizia); 
Training on various aspects of biotechnology e.g. 
microbial  genetics.  plant  biotechnology  (tree 
improvement).  collection  and  preservation  of 
seeds; 
Development  of  EPA/DHA  production  from 
flshery industrial wastes; 
Economic  evaluation  of  amyloglucosidase 
production; 
Enhancement  of biological  nitrogen  flxation  of 
soybean in Indonesia. particularly in acid soils of 
Sumatra; 
Production of starch hydrolytic enzymes by liquid 
substrate fermentation; 
Biotechnology  and  development  of species  for 
industrial timber estate; 
Exploration  and  preservation  of  tropical  fruit 
(citrus). 
6.  Improvement of low nutrient feed using  fermen-
tation technology; 
Production of mannanase; 
Embryo transfer; 
Production of phytase for  improving the nutrient 
quality ofrice bran; 
Production  of cassava-protein:  fermentation  of 
cassava using Aspergillus roger. 
7.  Cloning  DNA  encoding  fimbrial  antigens  of 
enterotoxigenic Escherichia coli causing neonatal 
diarrhoea in piglets and calves; 
Production  and  characterisation  of monoclonal 
antibodies to fimbrial  antigens of enterotoxigenic 
Escherichia. coli; 
Production  and  characterisation  of  monoclonal 
antibodies to Brucella abortus. 
8.  Micropropagation  of selected estate crops  using 
cell suspension techniques; 
Development  of molecular  markers  for  disease 
resistance  to  Corynespora  using  RFLP/RAPD 
techniques; 
Bioconversion  of  cocoa  for  flavouring  agent 
production by immobilised cell technique; 
Production of plantlets of coconut, oil palm and 
robusta coffee; 
Advisory  services  on  technology  application  in 
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estate waste utilisation fermentation. biocontrol of 
diseases and micropropagation of estate crops; 
Increasing the resistance of Arabia coffee against 
nematode; 
Development of carrier formula for microbes  to 
provide  a high viability  of bacterial  and  fungal 
inoculants; 
DNA mapping of oil palm resistant to Ganoderma 
disease; 
Adoption  of  biotechnological  methods  for  oil 
palm improvement; 
Bioreactor  micropropagation  of elite  tea clones 
through somatic embryogenesis. 
9.  Microbial fermentation (11 titles); 
Enzyme technology (7 titles); 
Genetic engineering (5 titles); 
Biological wastewater treatment (7 titles); 
Short courses on fermentation technology; 
Short courses on molecular biology; 
Internship  program  in  genetic  engineering.  for 
faculty members of other universities; 
Internship  program  in biochemistry.  for  faculty 
members of  other universities; 
Internship  program  in wastewater  treatment.  for 
faculty members of other universities; 
Development of  diagnostic probe for my; 
Development of diagnostic probe for Salmonella; 
Treatment  for  palm  oil  industry  effluent  using 
anaerobic and aerobic process; 
Design  of  wastewater  treatment  plant  for  the 
Oberoi Hotel in Bali; 
Design  of wastewater  treatment  plant for  a  car 
manufacturing plant in Jakarta; 
Microbial transformation of solasodine; 
Conversion  of  carbohydrate  into  high  fructose 
syrup by enzyme reaction; 
Isolation  and  characterization  of dehalogenating 
microbes from local resources; 
Degradation of organochlorine compounds using 
the dehalogenating microbes. 
10.  Fodder yeasts; 
Lignin  (rice  straw)  decomposition  by  soil 
microbes; 
Nangka powder fermentation to glucose syrup by 
Saccharomyces cerevisiae; 
Small  scale  industry  training  on  process  tech-
nology of tempe and tofu production. 
11. The improvement and the application of biorepro-
ductive  technology  for  increasing  sheep produc-
tivity; Improving  productivity  of sheep  and  goat  by 
frozen embryo; 
Embryo transfer in dairy cattle by frozen embryo; 
Training on artificial insemination. 
12.  Study of media formulation for stimulating callus 
of Gnetum gnemon (mlin  jo) seeds; 
Preliminary  study  for  amylase  production  from 
recombinant. 
13. Study to obtain salt tolerant rice variety; 
Callus induction to increase secondary metabolite 
in carrots; 
Protoplast culture in vegetables. 
14.  Penicillin production by Penicillium chrysogenum 
strain ATCC 26818 in batch system; 
Pnxluction  of  entomopatbogen  Bacillus  thurin-
giensis through fermentation technology; 
The use of somaclonal variation to  produce acid 
tolerant soybean plant; 
The  use  of  somaclonal  variation  to  produce 
Fusarium toxin tolerant tomato plant; 
Penicillin production by Penicillium chrysogenum 
strain ATCC 261818 in batch system; 
Agriculture research management project. 
15. Purification  and  detection  of Baculovirus  with 
monoclonal antibody; 
Development  of  monoclonal  antibody  for 
detection of CVPD - free citrus seedling stocks; 
PCR  for  detection  of  CVPD  causing  agent  in 
citrus seedlings; 
Transfer  of SMZ  coat  protein  gene  for  devel-
opment of soybean tolerant to viral infection; 
Production of Rhizobium inoculum; 
Teclmology for Azolla mass production; 
Production of oyster mushroom spawn; 
Information,  dissemination  and  training  for 
Rhizobium inoculum application; 
Training  for  integrated  pest  management 
(Biological control, etc); 
Tissue culture of garlic for virus  free  stocks and 
production of monoclonal antibody for latent 
VlruSes. 




17.  Agricultural Biotechnology; 
Animal Biotechnology; 
Industrial Biotechnology; 
Biopreservative potentials of lactic acid bacteria; 
Cell fusion of  A. niger and A. oryzae; 
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Monoclonal antibody for aflatoxin detection; 
Fish fermentation technology; 
Culture collection and their distribution; 
Id(""I1tification of microbes; 
Bacteriocins as food preservatives. 
18. Genetic  analysis  of  inherited  diseases  Waard-
enburg syndrome & Thalassemia; 
Production  of  monoc1onal  antibodies  against 
dengue viral antigens and filarial antigens; 
Development of early diagnostic tools by amplifi-
cation  of minicircle  DNA  using  PCR  for  surra 
diseases; 
Production of erythromycin; 
Production of bioinsecticide (BT toxin); 
Supporting  the  university  staff  development 
program; 
Supporting  the  research  facility  for  graduates 
program; 
Establishment of linkages with industry and insti-
tutes; 
Genetic counselling; 
Development of flower biotechnology. A collabo-
rative  program  between  mC-Biotechnology  and 
Binektra Foundation; 
Prevalence and genetic variation of thalassemia in 
Indonesia  (with  MRC  Molecular  Haematology 
Unit, IMM Oxford, UK); 
Genetic analysis of Warrdenburg Syndrome (with 
Michigan State University, USA); 
Biodiversity  (with  International  Institute  for 
Biotechnology. Canterbury, UK). 
19. Sugarcane tissue culture; 
Micropropagation of Durio zibetinus; 
Micropropagation of Gnetum gnemon; 
Micropropagation of Salacca edulis. 
20. Development  of  technology  for  starter  and 
enzyme production for dairy industry; 
Manipulation of rumen micro  flora  for enhancing 
cattle production; 
NUFFIC; 
Agricultural Research and Management Project; 
Fish sauce fermentation. 
21.  Multiplication of rami through tissue culture; 
Multiplication of tobacco; 
Multiplication of Carna vaccine; 
Callus,  plantlets,  vaccine  for  cucumber  and 
zucchini. 
22. Microbial  dextranase  production  using  genetic 
engineering techniques; 
Xanthan gum production from sugarcane products 
and by-products; Use of molecular approach to  enhance the sugar-
cane breeding program; 
Wastewater treatment; 
Evaluation  of  USAB  system  at  Madukismo 
alcohol factory; 
Test of biocides in sugar factories. 
3. What national priorities for biotechnology research 
have been identified or articulated by the 
government? 
See main text. Section 4 
4. What national programs in biotechnology have 
been set up and how muchfunding has been allocated 
for the program? 
National Program on Biotechnology begins in April 95 
and  is  funded  to  1999-about  200,000  million 
Rupiahs. 
5. Does the country have any biosafety regulations, 
protocols or guidelines for biotechnology. If  so, what 
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form does this take (e.g. expert committee, 
consultants, government review, permits). If  not. is the 
country presently drafting any guidelines or 
regulations? 
Biosafety  regulation  comprises  of  ad  hoc  expert 
committees and  the  Directorate of Quarantine or the 
National  Research  Council.  The  committees  report 
and make recommendations to the relevant Minister. 
6. Does the country have any intellectual property 
righJs for biotechnology? If  so, what form does this 
take (e.g. patents, plant variety righJs)? 
There is  no  patent protection legislation for  biotech-
nology in Indonesia. 
7. Is the country a signatory to the Convention on 
Biodiversity? If  so, does the country have. or is it 
planning to draft. protocols for biodiversity? 
Yes,  Indonesia  has  ratified  the  Biodiversity  Con-
vention. Appendix 7 
MALAYSIA 
1. Please list the main  facilities, research centres and 
institutions engaged in agricultural biotechnology 
research. 
1.  University:  Universiti  Kebangsaan  Malaysia 
(UKM), University Malaya (UM); 
2.  Universiti  Sains  Malaysia  (USM),  Universiti 
Pertanian Malaysia (UPM); 
3.  Universiti  MAS  new Sarawak campus  has just 
been established; 
4.  Institute:  Forest  Research  Institute  of Malaysia 
(PRIM); 
5  Palm Oil Research Institute of Malaysia (PORIM); 
6  Rubber Research Institute of Malaysia (RRIM); 
7.  Malaysian  Agricultural  Research  and  Develop-
ment Institute (MARDI); 
8.  Veterinary Research Institute; 
2. What biotechnology research activities are 
conducted in these centres andfacilities? 
Very  broad  including  animals,  flowers,  fruits,  rice, 
vaccine  production,  embryo  transfer,  tissue  culture 
and waste technology. Malaysia's new policy is not to 
open new land for agriculture to  increase production 
but to utilise idle land and increase yield by more high 
yielding strains. 
3. What national priorities for biotechnology research 
have been identified or articulated by the 
government? 
The  National  Biotechnology  Working  Group  have 
identified  the  following  priorities  for  plant biotech-
nology: 
•  in vitro tissue culture 
•  DNA marker technology 
•  genetic engineering 
•  cyopreservation 
•  protein studies 
Priorities for animal biotechnology set by the Animal 
Working Group include: 
•  Animal nutrition and production biotechnology 
•  enzymes and microbial additives 
•  growth promotants and regulators 
•  manipulation of  rumen ecosystems 
•  bioprocessing oflow quality feed 
•  Animal breeding and reproduction biotechnology 
•  conservation of genome DNA 
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•  COnservatiOI. of  sperm and embryos 
•  reproductive biotechnologies 
•  DNA recombinant technology including trans-
genesis 
•  Animal health biotechnology 
•  development of diagnostic reagents and kits 
•  development ofvaccines 
•  food safety 
•  Fish production and health biotechnology 
•  genetic improvement of selected foods and 
ornamental fish 
•  disease diagnosis and control 
•  conservation of genetic resources 
•  fish as a sensor of pollution 
4. What national programs in biotechnology have 
been set up and how much  funding has been allocated 
for the program? 
The  6th  Malaysian  Plan  (1991-1995)  allocated  $6 
million Ringgit to agriculture. Malaysia is setting up a 
National  Biotechnology  Directorate  headed  by 
Professor Latif which has  a budget of $100 million 
Ringgit  over  3  years.  The  Directorate,  under  the 
Ministry of Science and Technology and the Environ-
ment will take over all  the functions of the National 
Biotechnology  Working  Group  and  establish  a 
National  Biotechnology  Program. The objectives of 
the Directorate are: 
•  to  raise  the  reputation  of Malaysian  biotech-
nology so as to attract national and international 
investment; 
•  to encourage Malaysian industry to increase its 
investment in biotechnology R & D; and 
•  to  provide  an  optimal  infrastructure  for  the 
commercialisation of biotechnology R & D. 
Priority investment areas: 
•  diagnosis, vaccines and other health areas 
•  plant tissue culture scale up 
•  biotechnology of chemicals 
•  natural products screening and development 
•  environmental biotechnology 
5. Does the country have any biosafety regulations, 
protocols or guidelines for biotechnology. If  so, what 
form does this take (e.g. expert committee, 
consultants, government review, permits). If  not, is the 
country presently drafting any guidelines or 
regulations ? 
Malaysia is now in the process of making guidelines. 
There is a biosafety committee which is being incorpo-
rated  into  the  Government  (Ministry  of  Science, Teclmology & Environment),  and  will report  to  the 
Bioteclmology  Directorate.  Previously  this  function 
was  carried  out  by  the  National  Bioteclmology 
Working Group. 
6. Does the cOUlllry have any intellectUlll property 
rights for biotechnology. If  so, what form does this 
take (e.g. patenlS, planl variety rights). 
Malaysia does  not specifically have any intellectual 
property rights for biotechnology, but is covered by an 
Intellectual  Property  Rights  agreement  covering  all 
IPR.  Malaysia  will  be looking  to  have  an  !PR  for 
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bioteclmology  at  some  stage-Malaysia belongs  to 
the World Intellectual Property Organisation (WIPO). 
Intellectual  Property  comes  under  the  Ministry  of 
Domestic Trade & Consumer Affairs. 
7. Is the Counlry a signatory to the Convenlion on 
Biodiversity? If  so, does the counlry have, or is it 
planning to draft. protocols for biodiversity? 
Yes, Malaysia was one of the first to sign Convention 
on Biodiversity and is planning to draft protocols for 
biodiversity but does not currently have one. Appendix 8 
PHILIPPINES 
1. Please list the main  facilities, research centres and 
institutions engaged in agricultural biotechtwlogy 
research. 
Within the University of  the Philippines aJ Los Banos 
1.  Institutes  of  Biotechnology  and  Microbiology 
(BIOTECH); 
2.  Institute of Plant Breeding; 
3.  College of  Veterinary Medicine; 
4.  Institute of Animal Sciences; 
5.  Dairy Training & Research Institute; 
6.  Institute of Food Science; 
7.  National Crop Protection Center; 
8.  Institute of Biological Sciences; 
9.  PHlLRICE; 
Under the Department of  Science and Technology 
10. Industrial Technology and Development Institute; 
Other StaJe Colleges and Universities 
11. Central Luzon State University; 
12.  Visayas State College of Agriculture; 
13. Benguet State University; 
14. Central Mindanao University; 
15. University of Southern Mindanao; 
16. Mariano Marcos State University. 
2. WhaJ biotechnology research activity are conducted 
in these centres andfacilities? (the numbers in the 
margin refer 10 the institution in question 1) 
1.  Plant  tissue  culture of legumes  and ornamental, 
crop improvemem, vegetables and fruit, plantation 
crops and Rhizobium; 
2.  Plant tissue culture of legumes and omamentals, 
crop improvement, vegetables and fruit, plantation 
crops and Rhizobium; 
3.  Vaccines, diagnostics; 
4.  In-vitro fertilisation, embryo transfer; 
5.  Cheese and milk products; 
6.  Fermentation, food processing; 
7.  Integrated pest management; 
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8.  Genetic engineering-basic aspects; 
9.  Transgenic rice; 
10. Mushrooms; 
11.  Livestock-embryo  transfer;  fisheries--tilapia 
breeding, tissue culture; 
12. Biofertiliser, tissue culture; 
13. Tissue culture; 
14. Tissue culture; 
15. Tissue culture; 
16. Tissue culture. 
3. What naJional priorities for biotechtwlogy research 
have been identified or articuiaJed by the 
government? 
The Philippines  Agricultural Agenda  (1995-2000) is 
due for approval. This document articulates priorities 
and programs for biotechnology. 
4. What national programs in biotechnology have 
been set up and how much  funding has been allocated 
for the program? 
The Philippines Agricultural Agenda (1995.2000) is 
due fOT approval. This document articulates priorities 
and programs for biotechnology. 
5. Does the country have any biosafety regulaJions, 
protocols or guidelines for biotechnology. If  so, what 
form does this take (e.g. expert committee, 
consultants, government review, permits). If  not, is the 
country presently drafting any guidelines or 
reg ulations? 
The Philippines has biosafety guidelines and these are 
implemented by an expert committee. 
6. Does the country have any intellectual property 
rights for biotechnology. If  so, whaJ form does this 
take (e.g. patents, plant variety rights). 
The Philippines has IPR for biotechnology in the form 
of patents and plant variety rights. 
7. Is the Country a signaJory to the Convention on 
Biodiversity? If  so, does the country have, or is it 
planning to draft, protocols  for biodiversity? 
TIle  Philippines  has  signed  and  ratified  the  Con-
vention and has an existing protocol. Appendix 9 
THAILAND 
1. Please list the main  facilities, research centres and 
instructions engaged in agricultural biotechnology. 
1.1.  Universities  in Thailand engaged in agricultural 




Khon Kaen University, Khon Kaen 
Chiang Mai University, Chiang Mai 
Srinakharinwirot University Prasammit Campus 
Prince of Songkla University Hat Yai Campus 
Burapar University 
Naresuan University, Phitsanulok 
King Mongkut's Institute of Technology Thonburi 
King  Mongkut's  Institute  of  Technology  Lat 
Krabang 
Maejo Institute of Agricultural Technology, Chiang 
Mai 
Research activities  are  dissipated among various de-
partments and faculties in each university. 
1.2. Some government agencies are also engaged 
in agricultural  biotechnology research.  These are as 
follows: 
•  Ministry of  Agriculture and Cooperatives 
•  Department of Agriculture 
•  Department of Fisheries 
•  Department of Livestock Development 
•  The Royal Forest Department 
•  Ministry of  Science, Technology and Environment 
•  National  Centre  for  Generic  Engineering  and 
Biotechnology, National Science  and  Technol-
ogy Development Agency 
•  Thailand  Institute  of  Scientific  and  Tech-
nological Research 
2. What biotechnology research activities are 
conducted in these centres andfacilities? 




Animal breed improvement 
Embryo transfer 
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Animal health improvement 




Agricultural waste utilisation 
Development of biofertiliser 
Development of biopesticide 
3. What national priorities for biotechnology research 
have been identified or articulated by the 
government? 
Plant and plant product improvement 
Animal and animal product improvement 
Rural development and small farmers 
Sustainable development 
Health Improvement 
Novel  products  and  industrial  process  improve-
ment 
4. What national programs in biotechnology have 
been set up and how much funding has been allocated 
for the program. 
National centre for Genetic Engineering and Biotech-
nology  (NCGEB), National Science and Teehnology 
Development Agency,  is responsible in setting up the 
national programs in biotechnology for Thailand. This 
year NCGEB  has  about  100 million  baht allocated 
from the govemment and this will increase by around 
10% each year. 
5. Does the country have any biosafety regulations, 
protocols or guidelines for biotechnology. If  so, what 
form does this take (e.g. expert committee, 
consultants, government review, permits). 1f  not, is the 
country presently drafting any guidelines or 
regulations. 
The drafting of Biosafety guidelines was completed in 
1992. The guidelines cover  guidelines  for  laboratory 
practice  and  the  releases  of  genetically  modified 
organisms (GMOs) into the environment. The National 
Biosafety Commiuee (NBC) was established in  1993 
and also  the Institutional Biosafety Committee (!BC) 
at  various  universities,  government  departments, 
research  institutes,  regulatory  agencies  as  well  as 
private agencies was strongly recommended for estab-
lishment. 6. Does the country have any intellectual property 
rights for biotechnology. If  so, what form does this 
take (e.g. patents, plant variety rights)? 
Plant variety protection act is in the approval process 
by the government. 
7. Is the COUnlry a signatory to the Convenlion on 
Biodiversity.lf  so, does the cOunlry have or is it 
planning to draft protocols for biodiversity? 
It is a signatory of the Convention. Our government is 
still considering whether to ratify  the Convention on 
Biodiversity. 
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VIETNAM 
1. Please list the mainfad/ities, research centres and 
institutions engaged in agricultural biotechnology 
research. 
(Facilities  1-9 belong to  the Ministry of Agriculture 
and Food Industry (MAFl) 
L  Agricultural Genetic Institute (AGI) 
2.  National  Institute  of  Agricultural  Science  and 
Technology (INS A) 
3.  Postharvest Technology Institute (PTI) 
4.  National Institute of Plant Protection (NlPP) 
5.  Plant Protection Deparunent (PPD) 
6.  National Institute of Veterinary Research (NlVR) 
7.  Central Veterinary Medicinal Research Enterprise 
(CVMRE) 
8.  National Institute of Animal Husbandry (NlAH) 
9.  Institute of Agricultural Science of South Vietnam 
(JAS) 
10. Biotechnology Institute belonging to  the National 
Technology and Natural Science Centre (NTNCS) 
1  L  Tropical Biology Institute in South Vietnam (TBI) 
12. Nha Trang Ocean Research Institute (ORI) 
13. Mushroom  Research  Centre,  Biology  Faculty, 
National University of Hanoi (NUH) 
2. What biotechnology research aclivity are conducted 
in these centres alulfaciiities? 
1.  AGI:  research  on molecular  genetic  technology 
and plant gene technology, plant gene-bank and 
plant technology; 
2.  INS A:  research  on microorganism  and  microor-
ganism  gene-bank  for  plant  fertiliser  (fixed 
microorganic fertiliser, nitrogen, an easily digested 
fertiliser  phosphorus.  fertiliser  to  stimulate 
growth);  research  plant  gene  technology,  trans-
planting cell and plant gene-bank; 
3.  PTI:  research  on enzyme  technology,  biochem-
istry and entomology technology for rice,  maize, 
rootcrops.  peas,  beans-<:onservation  and  pro-
cessing  postharvest  agricultural  produce  with  a 
view to increasing nutrition; 
4.  NlPP: research biotechnology to produce all kinds 
of medicine  to  prevent  insects  in  the  field  to 
protect crops: rice, maize. vegetables and indus-
trial crops; 
5.  PPD: research biotechnology to produce medicine 
to protect plants and animals; 
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6.  NlVR:  research  on  microorganic  immWlisation 
technology  for  animals;  research  to  produce 
vaccine to protect and prevent disease in livestock; 
7.  CVMRE: research to produce veterinary medicine. 
produce all kinds to vaccine to protect and prevent 
disease in livestock; 
8.  NlAH: research on biotechnology of animals and 
animal gene-bank; 
9.  IAS:  research  on  biotechnology  for  plants  and 
plant gene; animal biotechnology and animal gene; 
10. NTNCS:  research  on  plant  biotechnology  and 
plant  gene-bank;  research  on  animal  biotech-
nology and animal gene-bank, mainly for cattle; 
11. TBI:  research  on plant biotechnology and  trans-
plant cell technology; research the technology of 
all kinds of medicine production to prevent inseets 
in  plants;  research  on  enzyme  technology  for 
processing agricultural produce; 
12. ORI:  research  on  biotechnology  to  exploit  the 
sea's natural resources. 
3. What national priorities for biotechnology research 
have been identified or articulated by the 
government? 
A  (translated)  extract  from  Government  Resolution 
number I8/CP of 11  March 1994. on 'Biotechnology 
Development  in  Vietnam  to  year  2010'  is  copied 
below: 
m. Content  of the  Biotechnology  Development  in 
Vietnam to the year 2010 
1)  Biotechnology  to  serve  agriculture.  forestry 
and fisheries development; 
2)  Biotechnology to serve health of the people; 
3)  Biotechnology  to  serve  protection  of living 
environment and natural bioresources; 
4)  Biotechnology to serve other industries; 
5)  Building  up  scientific  and  technological 
capabilities in the field of biotechnology; 
6)  Building up of biotechnology industry. 
4. What national progratns in biotechnology have 
been set up and how muchfunding has been allocated 
for the program? 
A (translated) extract from the five year program KC-
08  (1991-1995)  is  copied below.  Or Nguyen Thien 
Luan,  Vice  Minister,  MAFI.  is  chairman  of  this 
program. Details of funds are not available. 
IV.  Biotechnology Program-12 main topics 
1)  Research  on  technological  method  for  cell 
duplication  in  fruit  crops,  forest  trees  and 
medical plants; 2)  Use cell technology in creating high resistant 
crop varieties for droughts, cold and hot weather; 
3)  Research  to  complete  technology  on  new 
breeds of  cattle and increased growth of fish; 
4)  Technology to  redevelop DNA variety which 
has  high resistance,  high productivity  and  good 
quality; 
5)  Research and classify new varieties in micro-
biology  to produce  fertiliser  to  exploit  biotech-
nology and food stuff industry; 
6)  Research and apply biotechnology to produce 
biology production in order to protect plants and 
conserve and process agricultural products; 
7)  Research  and  apply  the  good  varieties  to 
increase protein in foodstuffs; 
8)  Research  new  varieties  of rare  mushrooms 
and methods to stop disease of these mushrooms 
in production; 
9)  Research  production  technology  and  apply 
'proteinaza-inhibito' in medicine and agriculture; 
10) Research  enzyme  technology  to  process  the 
products which have high protein and amino acid 
for human and animals; 
11) Research product technology which have high 
nutrition for human and animals; 
12) Research  to  improve  tetradoxin  products 
technology. 
A Committee on Biotechnology has been established 
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by the National Assembly. This committee will assess 
policy in the use of Biotechnology in Vietnam. 
5. Does Vietnam have any biosafety regulations, 
protocols or guidelines for biotechnology. If  so, what 
form does this take (  e.g. expert committee, 
cOTlSultanJs, government review, permits). If  not, is 
Vtelnam presently drafting any guidelines or 
regulations? 
The  government  has  an  ordinance  to  protect  and 
guarantee  animals  and  plants  and  an  ordinance  for 
veterinary research. The Plant Protection Department 
and Veterinary Research Department control imports 
of plants and animals. 
6. Does Vietnam have any inJellectual property rights 
for biotechnology. If  so, what  farm does this take (e.g. 
patenJs, plant variety rights)? 
The Parliament Committee of the National Assembly 
has  promulgated a decree  on protection of all  intel-
lectual  property  rights.  This  decree  has  two  ordin-
ances: (l) protection of inventions; and (2) protection 
of utilities solution. Protection is by patents. 
7. Is Vietnam a signatory to the ConvenJion on 
Biodiversity?  If  so, does Vtetnam have, or is it 
planning to draft, protocols for biodiversity? 
Vietnam  is  a  signatory  and  has  also  ratifed  the 
Convention. Appendix 11 
Summary ofInternational Agricultural Biotechnology Initiatives 
AGRICULTURAL REGION I 
NAME  FOCUS  COUNTRY 
(host institution)  PRIORffiES  (crop I livestock)  FOCUS 
CROP RESEARCH PROGRAMMES 
Agricultural Biotechnology 
for Sustainable Productivity, 
ABSP (Michigan State University) 
BeanlCowpea Collaborative 
Research Support 
Program, B/C CRSP 
(various US universities) 
• genetic engineering of  crops for 
pest/disease resistance 
• development of micropropagation 
systems 
• integration of biotechnology within a 




• technology transfer 
• control of pests and diseases 
• increase crop yields 










Biotechnology-Assisted Breeding  • durable resistance to pests and diseases  potato 
to Reduce Pesticide Use in Potatoes' integrated pest management 
(CIP) 
Centre for the Application of 
Molecular Biology to International 
Agriculture, CAMBIA 
CATIE - Biotechnology Unit 
CIAT - Biotechnology 
Research Unit 
CIRAD - Plant Breeding Division 
• novel biotechnologies and methods 
for agricultural irmovation 






• enhance regional program capabilities  banana/plantains 
• genetic improvement of tropical crops  coffee 
cocoa 
• increasing the efficiency of  CIAT 
strategy research 
• institutional development of 
biotechnology 
• develop genetically improved crops 
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international Feathery Motde VIlUS Resistant  • human resource development  sweet potato  Kenya 
Sweet Potato for African Farmers  • production of  virus-resistant, 
(USAID)  African varieties of  sweet potato 
• enhance capacity in biosafety 
regulation of transgenic crop plants 
• export of transgenic sweet potato 
to Africa for field testing 
• technology transfer 
ICGEB  Plant Biotechnology  • capacity building  rice  international 
Sub-Programme  • genetically improved rice 
ICRISAT - Biotechnology  • support and complement conventional  sorghum  international 
crop improvement programs  pearl millet 
at ICRISAT  groundnut 
chickpea 
pigeonpea 
IIRSDA  • conservation and characterisation  yam  Sub-Saharan 
Plant Biotechnology Program  of  yam germplasm  African eggplant  Africa 
• micropropagation and genetic 
improvement of yanl and other crops 
IITA- • tackle recalcitrant problems in  cowpea  Sub-Saharan 
Biotechnology Research Unit  crop improvement  yam  Africa 
• enhance national research capabilities  cassava 
banana/plantain 
International Laboratory for  • genetically engineered food crops  rice  international 
Tropical Agricultural  with virus resistance  cassava 
Biotechnology,ILTAB  tomato 
(Scripps Research Institute)  sugarcane 
International Program on  • rice genetic improvement  rice  international 
Rice Biotechnology  • capacity building 
(Rockefeller Foundation) 
International Service for the  • acquisition and transfer of near-term  vegetables  international 
Acquisition of Agri-biotech  applications of agricultural  fruits 
Applications, ISAAA  biotechnology applications,  field crops 
(Cornell University)  particularly proprietary technology  agroforestry 
• biosafety 
aDA Plant Sciences Research  • genetically improved crops  cereals  Cote d'Ivoire 
Programme (University of Wales)  roots &  tubers  Niger 
legumes  India 
oilseeds  Nepal 
fruit & vegetables  Pakistan 
fibres  Peru 
51 Reducing Maize Losses to Insect  • enhanced insect-resistance maize  maize  international 
Pests by Enhancing Host Plant  germplasm 
Resistance with Bacillus 
thuringiensis Toxin Genes 
(CIMMYT) 
Regional Program of  • collaborative research projects  maize  Latin 
Biotechnology for Latin American  • training  potato  American & 
(several UN organisations)  sugarcane  the Caribbean 
LIVESTOCK RESEARCH PROGRAMMES 
CIRAD- • development of heat-stable vaccines  cowdriosis  international 
Animal Production Division  through genetic engineering  dermatophilosis 
• improved diagnostic tests  rinderpest 
• determination of genetic resistance  peste des petits 
to diseases  ruminants 
mycoplasmosis 
trypanosomiasis 
International Laboratory of  • live recombinant virus vaccines  rinderpest  international 
Molecular Biology for Tropical  for animal diseases  bovine virus 
Disease Agents, ILMB  • technology transfer  diarrhoea 
(University of California)  equine influenza 
peste des petits 
ruminants 




ILRAD- • novel vaccines  theileriosis  international 
Tick-Borne Diseases Program  • improve current control methods  cowdriosis 
anaplasmosis 
babesiosis 
ILRAD- • improve diagnosis and parasite  trypanosomiasis  international 
Trypanosomiasis Program  characterisation 
• novel vaccines 
• breeding for genetic resistance 
Indo-Swiss Collaboration in  • capacity building  foot and mouth  India 
Biotechnology, IS CB  • animal disease diagnostics  disease 
(Swiss Federal Institute  and vaccines  contagious caprine 
of Technology)  • biopes tic ides  pleuropneumonia 
Small Ruminant Collaborative  • improve the efficiency of milk and  heartwater  Kenya 
Research Support Program,  meat production from small ruminants  contagious caprine Indonesia 
SR CRSP - Animal Health  • virus-vectored vaccines for  pleuropneumonia  Bolivia 
Component  sheep and goats  Nairobi sheep 
(Washington State University)  disease 
52 Tickborne Diseases Vaccine  • development and commercialisation  heartwater  Egypt 
Development Program  of improved vaccines and  anaplasmosis  Mali 






Biotechnology Advisory  • review biotechnology projects  international 
Commission, BAC (Stockholm  involving field testing and/or the 
Environment Institute)  pI armed introduction of  genetically 
modified organisms 
Intermediary Biotechnology  • biotechnology research program  international 
Service, IBS  management and policy formulation 
(ISNAR)  • country reviews 
• identify international program expertise 
Support to Agricultural  • biosafety, IPR  Latin 
Biotechnology Policies  • industry development  America & 
(IICA)  the Caribbean 
NETWORKS 
African Biosciences Network  • genetically improved crops  Africa 
Sub-Network for Biotechnology,  and farm animals 
ABN-BIOTECHNET  • disease control through new vaccines 
(University of Nigeria)  • capacity building 
Asia Network for Small-Scale  • plant tissue culture  potato  Asia 
Agricultural Biotechnologies,  • biopesticides  kapok tree 
ANSAB  • biofertilisers  rice 
• mushroom technology  mushroom 
Asian Rice Biotechnology  • DNA fingerprinting of pests and  rice  Asia 
Network, ARBN (IRRI)  pathogens 
• low-cost marker-aided selection 
• transgenic rice 
Phaseolus Bean Advanced  • constraint identification  beans  international 
Biotechnology Research Network,  • technology transfer 
BARN (CIAT)  • information exchange 
Cassava Biotechnology  • stimulate cassava biotechnology  cassava  international 
Network, CBN (CIAT)  research on priority topics 
• integrate priorities of small-scale 
fanners, processors, and consumers in 
cassava biotechnology research planning 
• information exchange 
53 Technical Cooperation Network on  • generation. transfer and application  vegetables  Latin 
Plant Biotechnology, REDBIO  of  plant biotechnology  roots & tubers  American & 
(FAO/RLAC)  • national and regional policies  cereals  the Caribbean 
• information exchange 
DONOR AGENCIES 
Australian Centre for International  • use biotechnology wherever  international 
Agricultural Research, ACIAR  appropriate as a research tool within 
any of ACIAR's projects 
DGIS Special Programme  • improve developing-country access  "orphan"  Colombia 
Biotechnology and Development  to biotechnology, with special  commodities  India 
Cooperation (Ministry of Foreign  emphasison small-scale  cassava  Kenya 
Affairs, The Netherlands)  producers and women  Zimbabwe 
• technical cooperation 
• international collaboration and 
coordination 
FAO/AGP Programme on Plant  • information dissemination and  rice  international 
Biotechnology (Food and  cooperation  roots & .tubers 
Agriculture Organisation of the  • advisory services  horticulture 
United Nations)  • capacity building  industrial crops 
• promote research, technology 
transfer and adoption 
United Nations Development  • productive and sustainable agriculture  food crops  international 
Programme  cash crops 
livestock 
World Bank  • invest in biotechnology as a  international 
contribution to economic development 
in World Bank member countries 
CATIE =  Centro Agronomico Tropical de Investigacion y Ensenanu; CIAT =  International Centre for Tropical Agriculture; CIMMYT = 
Internatiooal Centre for Maize and Wheat Improvement; CIP =  International Potato Centre; ORAD  Centre de cooperation internatiooale en 
recherche agronomique pour le developpement; FAO/AGP = UN Food and Agriculture Organization. Plant Production and Protectioo Division: 
FAOIRLAC = UN Food and Agricultural Organisation, Regional Office for Latin America and the Caribbean; ICGEB = International Centre for 
Genetic Engineering and Biotechnology; ICRlSAT = International Crop Research Institute for the Semi-Arid Tropics; IICA =  Interamerican 
Institute for Cooperation in Agriculture; IIRSDA = Institut international de recherche scientiflque poor le developpement en Afrique; IITA = 
Intcmatiooallnstitute for Tropical Agriculture; ILRAD = International Laboratory for Research on Animal Diseases; IRRl = International Rice 
Research Institute; ISNAR =  Internatiooal Service for National Agricultural Research; ODA =  Oven;eas Development Administration (UK); 
USAID =  United States Agency for International Development. 
Note: For the purpose of the survey, ACIAR was considered as a donor agency as it does not conduct its own research, but arranges collaborative 
research projects between scientists wmking in existing research institutions in Australia and in the overseas partner countries. 
54 Appendix 12 
CONVENTION ON BIOLOGICAL DIVERSITY 
(Rio de Janeiro, 5 June 1992)  Updated 20 April 1995 
Developing countries within ACIAR's mandate excluding South and Latin American, 
and West African countries 


































5 lun 1992 
5 lun 1992 
11 Inn 1992 
11 lun 1992 
12 lun 1992 
90ct 1992 
5 lun 1992 
5 lun 1992 
11 Jun 1992 
11 Jnn 1992 
12Jun 1992 
12Jun 1992 
12 Jun 1992 
121un 1992 
11 lun 1992 
121un 1992 
5 Inn 1992 
13 Inn 1992 
121un 1992 
12 lun 1992 
13 lun 1992 
10 Iun 1992 
121un 1992 
12 Jun 1992 
8 lun 1992 
9 Jun 1992 
28 May 1993 
11 Jun 1992 






18 Jun 1993 
3 May 1994 
9 Feb 1995(a) 
5 Jan 1993 
20 Apr 1993 
25 Feb 1993 
18 Feb 1994 
23 Aug 1994 
12Nov 1993 
26 Jul1994 
16 Aug 1994(a) 
24Jun 1994 
9 Nov 1992 
20Jnn 1994 




16 Mar 1993 
8 Get 1993 
9 Feb 1994 
23 Mar 1994 
25 Mar 1993 
16 Nov 1994 
28 May 1993 
11 Nov 1994 